## **Laurence Morel, Ph.D.**

Female

US citizen

**Current Position:**

Mary and Ryan Whisenant Family Professor of Pathology, Department of Pathology, Immunology, and Laboratory Medicine University of Florida

Vice Chair for Research and Academic Affairs, Department of Pathology, Immunology, and Laboratory Medicine University of Florida

**Business Address:**

Department of Pathology, Immunology, and Laboratory Medicine

University of Florida

1600 Archer Rd

Gainesville, Fl, 32610-0275

Tel: (352) 372-3790

Mobile: (352) 213-3752

Fax: (352) 372-3053

e-mail: [morel@ufl.edu](mailto:morel@ufl.edu)

**EDUCATION**:

Universite Aix-Marseille II: DEUG in Biology, 1978

Universite Aix-Marseille I: Master degree in Animal Biology, 1980

Universite Aix-Marseille II: PhD in Neuroscience/ Behavioral Sciences, 1983

**APPOINTMENTS**:

* Foreign Research Visitor, Department of Entomology, University of Georgia, 1985-1986.
* Post-doctoral Assistant, Department of Pathology and Laboratory Medicine, College of Medicine, University of Florida, 1991-1992.
* Visiting Assistant IN, The postdoctoral program of the Department of Pathology and Laboratory Medicine, College of Medicine, University of Florida, 1993-1996.
* Assistant Scientist, Department of Pathology and Laboratory Medicine, College of Medicine, University of Florida, 1996-1998.
* Member of the Center for Mammalian Genetics, 1996-2005.
* Assistant Professor, Departments of Medicine, and Pathology, Immunology, and Laboratory Medicine University of Florida, January 1999-2004.
* Graduate Faculty member, Inter Disciplinary Graduate Program, College of Medicine, University of Florida, June 1999-date.
* Member of the Genetics Institute, 2000-date.
* Co-Director of the Immunology and Microbiology Inter Disciplinary Program Advanced Concentration, 2002-2009.
* Associate Professor, Department of Pathology, Immunology, and Laboratory Medicine University of Florida, January 2004-2007.
* Associate Director of the Division of Experimental Pathology, Department of Pathology, Immunology, and Laboratory Medicine, 2005-2007.
* Professor, Department of Pathology, Immunology, and Laboratory Medicine University of Florida, May 2007-date.
* Director of the Division of Experimental Pathology, Department of Pathology, Immunology, and Laboratory Medicine, July 2007-2017
* Member of the Center for Immunology and Transplantation, 2007-date.
* Mary and Ryan Whisenant Family Chair in Experimental Pathology, December 2008 - date
* Advisory Board Member of the Center for Mucosal Immunology and Inflammation, 2012-date.
* Vice Chair for Research and Academic Affairs, Department of Pathology, Immunology, and Laboratory Medicine, 2017-date.

**ACADEMIC AND PROFESSIONAL HONORS**

* Doctoral dissertation grant, Direction Generale de la Recherche Scientifique et Technique, France 1981.
* Research Grant, Societe des Amis des Sciences, France. 1983
* Research Grant, Fondation Singer-Polignac, France. 1985
* Foreign Research Visitor Grant, Formation des Francais a l’Etranger, Ministere des Relations Exterieures, France. 1985
* Research Grant, Fondation Les Treilles, France. 1986
* Grinter Scholar, Graduate School of the University of Florida. 1988-1991
* National Research Service Award fellowship, National Institute of Allergy and Infectious Diseases. Project title: “Mapping susceptibility genes of murine SLE”. 1993-1996
* Arthritis Investigator Award, Arthritis Foundation. Project title: “Genetic characterization of a major SLE-susceptibility locus on mouse chromosome 1". 1996-1999
* Howard Hughes Research Resources Program Pilot Project Award. Project title: “Functional and Genetic characterization of autoimmune and tumorigenic on murine chromosome 4". 1999
* College of Medicine Incentive Fund Award: Delineation of SLE functional pathways using cDNAs microarrays. 1999
* American Cancer Society –18th International Cancer Congress Travel Award. 2001
* Department of Pathology Faculty Council representative. 2004-2007.
* Faculty of 1000 Biology: Member, 2006-date.
* Elected Member of the Henry Kunkel Society for Clinical Immunology, 2006.
* University of Florida Faculty Recognition Award, 2007
* Exemplary Teacher Award, UF College of Medicine. 2006-2007
* UF College of Medicine Faculty Research Prize Basic Science, 2006-2007
* Exemplary Teacher Awards, UF College of Medicine 2004, 2007; 2008; 2009; 2010, 2011.
* University of Florida Research Foundation member, 2008-2011.
* Appointment to the Mary and Ryan Whisenant Family Chair in Experimental Pathology, December 2008.
* Elected to the AAI Education Committee, 2010-2012.
* Elected Henry Kunkel Society Councilor, 2014-2017
* UF Term Professorship, 2017-2020.
* Appointed to the AAI Publication committee 2019-2021.
* Elected Vice-President of the International Association for Comparative Medicine, 2019.

**UNIVERSITY OF FLORIDA GOVERNANCE**

* College of Medicine Promotion and Tenure Committee ad hoc member, 2005.
* UF COM Faculty Council, Department of Pathology elected representative, 2005-2008.
* College of Medicine Promotion and Tenure Committee elected member, 2008-2010.
* Thomas H. Maren Junior Investigator award Committee Member, Fall 2009.
* Thomas H. Maren Postdoctoral fellowship award Committee Member, Spring 2011.
* University of Florida Graduate faculty Mentoring Award Committee Member, Spring 2011.
* University of Florida Searle Scholars Program Committee Member, Summer 2012
* [Pew Scholars Program in the Biomedical Sciences](http://my.research.ufl.edu/Applications/FundingOpportunities/ArticleDetail.aspx?id=28850) Program Committee Member, Summer 2012.
* UF COM Research Leadership committee: 2012-present.
* Opportunity Fund grant review, March 2013.
* Center for Mucosal Immunology and Inflammation retreat planning committee. 2013-present.
* [Pew Scholars Program in the Biomedical Sciences](http://my.research.ufl.edu/Applications/FundingOpportunities/ArticleDetail.aspx?id=28850) Program Committee Member, June 2014.
* UF Advanced Leadership program graduate, 2014
* UF Research Foundation COM selection committee
* Medical Guild MSI competition judge
* COM WIMS leadership group 2016-2017.

**UNIVERSITY OF FLORIDA SEARCH COMMITTEES:**

* Member, Dermatology Division Chief, Department of Medicine, 2003
* Member, Molecular Genetics and Microbiology faculty recruitment, 2005
* Member, Ethel Smith Chair in Vasculitis Research, Department of Medicine, 2006
* Member, Dermatology Division Chief, Department of Medicine, 2007-08
* Chair, Department of Pathology, Immunology, and Laboratory Medicine, Assistant Professor Faculty, Fall 2008.
* Member, Department of Pathology, Immunology, and Laboratory Medicine, Chief Administrative Officer, Spring 2009.
* Chair, Department of Pathology, Immunology, and Laboratory Medicine, Assistant Professor Faculty, Summer-Fall 2009.
* Chair, Department of Pathology, Immunology, and Laboratory Medicine, Research Assistant Professor Faculty, Summer 2009.
* Member, Department of Dermatology Chair, 2010.
* Chair, Department of Pathology, Immunology, and Laboratory Medicine, Associate Professor Faculty, Fall 2010/ Spring 2011.
* Member, Department of Pathology, Immunology, and Laboratory Medicine, Assistant Professor Faculty, Fall 2011.
* Member, Department of Pathology, Immunology, and Laboratory Medicine, Research Assistant Professor Faculty, Spring 2012.
* Member, Department of Pathology, Immunology, and Laboratory Medicine & CTSI, Research Assistant Professor Faculty, Spring 2012.
* Member, Department of Pathology, Immunology, and Laboratory Medicine, Molecular Pathology Division Director, Summer 2012
* Chair, Department of Pathology, Immunology, and Laboratory Medicine, Research Assistant Professor Faculty, Spring 2013.
* Chair, Mucosal Immunology/Host:Microbe Interaction Preeminence Initiative, Spring 2014 - present.
* Member, Department of Pathology, Immunology, and Laboratory Medicine, Clinical Assistant Professor, Fall 2014.
* Member, Department of Pathology, Immunology, and Laboratory Medicine, Clinical Assistant Professor, Spring 2015.
* Member, Department of Pathology, Immunology, and Laboratory Medicine, Clinical Assistant Professor, Spring 2016.
* Chair, Department of Pathology, Immunology, and Laboratory Medicine, senior Physician Scientist, 2016-2018.
* Chair, Department of Pathology, Immunology, and Laboratory Medicine, senior Viral Immunologist, 2017-2018.
* Department of Pathology, Immunology, and Laboratory Medicine, Research Assistant Scientists
  + Chair: 7
  + Member: 3
* Member, COM, Department of Medicine Chair, 2018.

**PROFESSIONAL MEMBERSHIPS:**

* American Association of Immunologists
* Elected to the Henry Kunkel Society, 2007-
* American College of Rheumatology

**REVIEW COMMITTEES/ ADVISORY PANELS:**

* National Arthritis Foundation, Molecular Biology and Genetics Study Section, 1999-2001.
* NIH-NIAID Ad Hoc review of a Program Project, March 2000 (declined because conflict of interest).
* NIH Immunological Sciences Special Emphasis Panel consultant, September 2000.
* NIH Immunological Sciences Study Section; October 2000, Temporary Member.
* NIH Immunological Sciences Special Emphasis Panel, November 2001
* Cooperative Grants Program of the U.S. Civilian Research and Development Foundation (CRDF), 2001.
* American Cancer Society, Leukemia, Immunology, and Blood Cell Development Study section January 2002-2004.
* NIH General Medicine Special Emphasis Panel, March 2002
* NIH/NIDDK Special Emphasis Panel, May 1 2002
* NIH/NIAMS Special Emphasis Panel, May 15 2002
* NIH/NIAMS Special Emphasis Panel, May 24 2002
* NIH IMS ad hoc study section member, Feb. 24, 2003.
* Welcome Trust ad hoc reviewer, May 2003
* Alliance for Lupus Research, Member of the Genetic Initiative discussion panel, NYC, NY, July 9 2004.
* NIH HAI study section member, 2004-2007.
* NIH/NIAMS Special Emphasis Panel, January 18, 2005
* Alliance for Lupus Research, study section member, 2005-2008.
* Biomedical Research Council (BMRC) in Singapore, ad hoc review, 2005.
* NIH/NIAMS Special Emphasis Panel, January 2006: declined because of conflict of interest.
* NIH/NIAMS CORT program project study section, March 13-15, 2006.
* VA Immunology A Review, May 9, 2006: invitation declined.
* Canadian Institutes of Health Research, Clinical Investigation committee, May 2006.
* United States-Israel Binational Science Foundation, Arthritis and rheumatism section, June 06.
* NIH ACTS member conflict (MOSS-K06), June 30th, 06.
* Peer-Reviewed Medical Research Program in the Department of Defense (PRMRDD) review panel of SLE, July 10-11, 2006: invitation declined.
* NIH/GGG-T62 Special Emphasis Panel, March 23, 2007.
* NIH ZRG1 GGG-T 90 Special Emphasis Panel, October 30, 2007.
* Arthritis Foundation, Molecular Biology and Genetics Study Section, October 24, 2007
* NIH ZAR1 MLB-G J1 1 Special Emphasis Panel, November 14, 2007.
* NIH NIAMS K award review panel, Spring 2008. Declined due to conflict of interest.
* DOD Lupus Investigator Initiated Research Award, September 14-16 2008.
* Welcome Trust, September 19, 2008.
* NIH GHD ad hoc study section member, October 6-7, 2008.
* ARRA Challenge grants ad hoc reviewer, spring 2009.
* Peer-Reviewed Medical Research Program in the Department of Defense (PRMRDD) review panel of SLE, July 19-21, 2009.
* NIH NIAMS GO RCA ARRA grant review, July 21-22, 2009.
* NIH GHD ad hoc study section member, October 10-11, 2009.
* NIH HAI ad hoc study section member, February 4-5, 2010
* NIH ZRG1 IMM-J(02)M Special Emphasis Panel, June 9, 2010
* PRMRP 2010 Concept Awards, July 2010
* Medical Research Council (UK) G1001193, August 2010
* PRMRP 2011 Lupus Panel, September 7, 2011
* NIH HAI ad hoc study section member, October 13-14, 2011
* Alliance for Lupus Research TIL grants, October 19, 2011.
* NIH 201201 ZRG1 IMM N04 Special Emphasis Panel, December 13, 2011, chair.
* NIH 2012/05 ZAI1 PA-I (M1) 1 - Antiviral Immunity Program Projects, February 6, 2012.
* NIH 2012 NIAMS P30 RDCC Review, June 13-14, 2012.
* Alliance for Lupus Research TIL grants, October 29, 2012.
* NIH 2013 **ZRG1 IMM-C (02) M** Special Emphasis Panel, March 1, 2013.
* NIH NIAMS PAR “Identification and Analysis of Causal Variants: Follow-Up on Genome-Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases”, April 8, 2013.
* NIH 2013 HAI Overflow Panel - ZRG1 HAI-K 08, June 7, 2013.
* NIH NIAID Stage 1 CETR, July 2013.
* Lupus Research Institute study section, September 11, 2013.
* NIH NIAID Program Project study section 2014/01 ZAI1 LGR-I (J1), September 16-17, 2013.
* Alliance for Lupus Research TIL grants, November, 2013.
* NIH HAI ad hoc study section member, February 6-7, 2014
* NIH NIAID PAR-13-254 (P01) study section member, June 2014.
* NIH HAI ad hoc study section member, June 6-7, 2014 (phone review)
* NIH ZRG1 GGG Q 50 Review Panel, July 17, 2014.
* NIH ZRG1 GGG Q 51 Review Panel, August 22, 2014
* Alliance for Lupus Research TIL grants, November 5, 2014.
* Dept. of Veterans Affairs 2015/01 IMMA 1 - Immunology and Dermatology A, December 3, 2014.
* NIH HAI ad hoc study section member, February 5-6, 2015.
* Roche Fund for research in personalized medicine, mail review, April 2015.
* NIH NIAID Program Project study section 2014/01 ZAI1 LGR-I (J1), June 15, 2015
* NIH IMM-S90S co-chair, October 29, 2015.
* NIH-NIAID PO1, January 28, 2016.
* NIH-NIAMS P30 RDCC Review, March 29-30, 2016.
* NIH-NIAID P50 Centers of Research Translation, April 8, 2016.
* NIH ACTS ad hoc study section member, June 14-15, 2016.
* NIH-NIAID member conflict SEP, October 28, 2016.
* NIH- NIAID PO1, January 25-26, 2017.
* French National Research Agency external reviewer 2017
* Alliance for Lupus Research TIL grants, May 24, 2017.
* NIH-NIAMS AMS review, June 22-23, 2017.
* NIH ACTS ad hoc study section member, March 10-11, 2018.
* NIH-NIAMS P30 RDCC Review, March 14-15, 2018.
* Lupus Research Alliance, TIL and NRG review, May 24-25, 2018.
* NIH-NIAMS AMS review, June 21-22, 2018.
* NIH-NIAMS ACE review December 3-4, 2018.
* Portuguese Marathon Lupus Panel
* NIH HAI ad hoc study section member, February 7-8, 2019.
* UF opportunity Funds April 29, 2019
* NIH-NIAMS AMS review, June 27-28, 2019
* NIH Special Emphasis Panel, November 20, 2019
* NIH NIAID Board of Scientific Counselors, ad hoc member, December 9-11, 2019.

**BRIEF DESCRIPTION OF JOB DUTIES -**

Since my appointment on a tenured-track position (1999), my majority of my duties have been devoted to research and graduate education. My research, which focuses on the genetic basis of autoimmune diseases in animal models, and more specifically Systemic Lupus Erythematosus, has been continuously and entirely funded by external peer-reviewed agencies (mostly NIH). I have been also heavily involved with graduate education through the UF COM Interdisciplinary Program (IDP) at various levels as detailed below. Finally, I have administrative duties (15% FTE) as the Vice-Chair for research and Academic Affairs Overseeing a > $18M budget in extra-mural funding, 22 tenure-track and 16 research track faculty members with basic research assignments, as well as the professional development portfolio for the entire Department.

**AREAS OF SPECIALIZATION -**

* + - Immunogenetics
    - Animal models of autoimmune diseases (mostly SLE)
    - Genetics of complex traits
    - Lupus pathogenesis
    - Immunometabolism
    - Microbiome in autoimmune diseases

**CURRENT GRANT SUPPORT:**

T32 DK108736 Atkinson (PI) 09/01/17-08/31/22

NIH

Interdisciplinary Graduate Program in Type 1 Diabetes and Biomedical Engineering

The goal of this proposal is to propose that a training program designed for co-mentoring of pre-doctoral students in an environment and culture providing strong interdisciplinary support for bioengineering and type 1 diabetes, will result in a new generation of researchers poised to contribute to a fuller understanding of, and new technologies for disease management, prevention and reversal.

Role: Mentor

R01AI143313-01 Morel (MPI) 01/15/19– 01/14/23

NIH

Gut dysbiosis and tryptophan metabolism in lupus

The goals of this proposal are to use a mouse model as well as samples collected from lupus patients to test the hypothesis that gut bacteria contribute to lupus by their utilization of tryptophan, an essential amino acid whose derivative metabolites activate immune cells.

R01 AI128901 Morel (PI) 09/01/16-08/31/21

NIH/NIAID

Targeting follicular helper CD4 T cells in SLE

The goal of the proposal is to prove the hypothesis that the elimination of lupus Tfh cells through glucose inhibition represents a safe therapeutic approach. We propose to test this hypothesis by characterizing lupus Tfh cells relative to Tfh cells induced by immunization in mouse models and cells obtained from lupus patients.

Role: PI

R01 AI045050-21 Morel (PI) 05/01/18-04/30/23

National Institutes of Health

Characterization of SLE-susceptibility loci on mouse chromosome 1

The project proposes to functionally characterize the *Sle1* cluster of SLE-susceptibility genes, including *Sle1a1* and *Sle1c2* in T cells*.* The discovery of the Pbx1 lupus susceptibility gene was achieved in this project. We are continuing to investigate the role of Pbx1 in T cells and there is no overlap with the current proposal.

Role: PI

R21 AR070660 Morel (PI) 05/13/16-04/30/18

NIH/NIAMS

Genetic Regulation of Mesenchymal Stem Cell Defects in Lupus

This proposal is designed to test the hypothesis that MSC defects induced by this gene contribute to lupus by promoting inflammation instead of immunosuppression, using a mouse model of lupus in novel experimental settings. It has great potentials to understand the genetic basis of abnormal MSC functions in lupus and help predict in which lupus patients cell therapy could be the most successful.

Role: PI

416522 Morel (PI) 09/01/16-08/31/19

ALR

Targeting follicular helper CD4 T cells in SLE

We propose the hypothesis that the elimination of lupus Tfh cells through glucose inhibition represents a safe therapeutic approach. We propose to test this hypothesis by characterizing lupus Tfh cells relative to Tfh cells induced by immunization in mouse models and cells obtained from lupus patients.

Role: PI

DRPD-ROF2017 Toth (PI) 06/01/17-05/31/19

UF Office of Research

Immune evasion mechanisms during oral infection by an oncogenic herpesvirus

The goals of this project are to characterize the immune response pathways inhibited by KSHV in human oral epithelial cells and to identify the viral genes responsible for this inhibition using a multidisciplinary approach combining expertise in KSHV biology (Toth), immunology (Morel) and genomic analysis (Papp)

Role: Co-Investigator

R01 HL133191 Herzog (PI)                      05/01/17-04/30/22

National Institutes of Health

Oral Tolerance of Hemophilia

Specific Aim 1 Develop the next generation of edible transplastomic plants expressing FVIII antigen,ovalbumin, or IL-10 fused to different transmucosal carriers, using cutting-edge chloroplast genetic engineering tools. Specific Aim 2 Continue to define the mechanism of oral tolerance induction/immune regulation, in part through use of a model antigen. Specific Aim 3 Further strengthen oral tolerance by enhancing immune regulation or manipulating T cell metabolism, thereby also providing further insights into the tolerance mechanism.

Role: Co-Investigator

**COMPLETED GRANT SUPPORT:**

R21 AI122338 Morel (PI) 01/04/16-12/31/18

NIH

Gut dysbiosis induces lupus

The project proposes to study how gut microbes contribute to disease in a mouse model of lupus. We have obtained preliminary data showing that mice with lupus have distinct gut microbes, which are sufficient to induce disease manifestation when transferred in healthy mice.

Role: PI

Preparatory Grant University of Florida Morel (PI) 05/15/15-05/14/17

Therapeutic Targeting of Immune Metabolism

The goal of this preparatory program were to develop the infrastructure and to generate critical preliminary data to allow our team to submit competitive program project grants (PPG) to the NIH and DOD within two years on the emerging field of immune metabolism.

Role: PI

296550 Morel (PI) 02/01/14-01/31/17

Alliance for Lupus Res.

High through-put screening to repurpose drugs for lupus therapeutics proposal

The overall goal of this proposal was to accelerate the speed by which new drugs with the potential to prevent and treat lupus are brought into the clinic.

Role: PI

Grifols, Inc. Song (PI) 01/23/2015-01/22/2016

The Protective Effect of Prolastin-C for the Treatment of Lupus

The overall goal of this proposal to test the effects and molecular mechanisms of Prolastin C on dendritic cells, and to evaluate the therapeutic effects of Prolastin C on lupus models. The ultimate goal of this study is to develop a novel therapy and pave the way for the treatment of lupus patients with Prolastin C.

Role: Co-Investigator

2R01 AI058150 02/10/2010-01/31/2015 3.6 calendar months

National Institutes of Health 3

**Role:** Principal Investigator

**Title:** Mechanisms of B cell Developmental defect in murine lupus

**Overall Goals:** This project proposes to define the mechanisms of B cell developmental defects in the NZM2410 model, specifically regarding B-1a and plasma cells, and to define the role of these defects in lupus pathogenesis.

ALR-TIL 0000075018 02/01/2013-01/31/2015 1.8 calendar months

Alliance for Lupus Research $184,681

**Role:** Principal Investigator

**Title:** CD4 T cell metabolism in SLE: Characterization and target identification

**Overall Goals:** We propose to characterize defects in CD4+ T cell metabolism in a mouse model of lupus and in lupus patients, and to explore whether treatment with metabolism inhibitors will reverse or alleviate lupus pathology in a mouse model.

Opportunity Fund 05/10/2012-04/30/2014 0.6 calendar months

UF DSR $44,000

**Role:** Co-Investigator

Role of Pbx1 regulation of MSC function in autoimmunity

Lupus Research Foundation 10/01/2013-09/30/2014 1.2 calendar months

**Role:** Principal Investigator

**Title:** Genetic regulation of stem cell dysfunction in a mouse model of lupus

**Overall Goals:** This proposal has great potentials to be translated into human studies and to predict in which SLE patient stem cell therapy will be successful and to expand the reach of lupus susceptibility genes from the immune system to stem cells.

R21 AR06681007/01/14-06/30/14 1.2 calendar months

NIH/NIAMS

**Role:** Principal Investigator

**Title:** G-CSF receptor regulation of neutrophils in lupus

**Overall Goals:** We have identified in a mutated form of a gene encoding for granulocyte-colony stimulating factor receptor (GCSFR) that suppresses lupus in the mouse. The growth factor (G-CSF) that binds to this receptor is known together up- or down regulate the immune system, but very little is known on its role in lupus. Moreover, G-CSF regulates the number and functions of neutrophils, a blood cell type that has been implicated in lupus pathogenesis. We propose to investigate how the G-CSF pathway controls lupus development and identify the role of neutrophils in this regulation. Results from this proposal will show how the G-CSF/G-CSFR pathway can be manipulated to counteract the development of lupus.

2R01 AI045050-16 (Morel) 05/01/2008-04/30/2013 3.6 calendar

National Institutes of Health $237,690 year 1-2, 327,686 year 3

**Role:** Principal Investigator

**Title:** Characterization of SLE-susceptibility loci on mouse chromosome 1

**Overall Goals:** This project proposes to characterize how two lupus susceptibility genes, Pbx1 and Esrrg, affect CD4 T cell tolerance in lupus-prone mice and lupus patients.

F31 AI094925 (Morel/Sang) 02/10/2012-02/09/2015 0.0 calendar

National Institutes of Health $34,959

**Role:** Mentor

**Title:** Mechanisms of B cell Developmental defect in murine lupus

**Overall Goals:** Fellowship to support graduate student Allison Sang

2R01 AI045050 Morel (PI) 05/01/08 to 04/30/13 3 calendar months

NIH/NIAID $291,068

**Role:** Principal Investigator

**Title:** Characterization of SLE-susceptibility loci on mouse chromosome 1

**Overall Goals:** The major goal of this project proposes to functionally characterize the *Sle1* cluster of SLE-susceptibility genes, including *Sle1a1*. This proposal, however, does not include any experiment that would investigate the role of retinoic acid in the function of *Sle1a1.* Some of the mouse strains and controls used in the LRI proposal will be provided through this NIH proposal.

RO1- AR44731 W. Reeves (PI) 9/26/06 to 08/31/11 0.6 Calendar months

NIH/NIAID $209,347

**Role:** Co-Principal Investigator

**Title:** Pathogenesis of Autoantibodies in Pristane-Induced Lupus

**Overall Goals:** The major goal of this project uses the pristane-induced autoimmunity mouse model to investigate the mechanisms by which pathogenic autoantibodies are produced.

Alliance for Lupus Research 2/1/08 TO 1/31/10 0.96 calendar months

K. Elkon, Univ. Washington, (PI) $500,000

**Role:** Co-Investigator

**Title:** Lysis of Immunostimulatory nucleoproteins in SLE Morel (PI)

**Overall Goals:** The major goals of this project will test the hypothesis that clearances of apoptotic materials through over-expression of DNAseI will be reduce lupus pathology in the NZM2410 mouse model.

TIL 113286*:* Morel (PI) 2/1/09 to 1/31/11 1.20 calendar months

Alliance for Lupus Research $206,027

**Role:** Principal Investigator

**Title:** Retinoic acid regulation of T cell homeostasis in Lupus

**Overall Goals:** The major goals of this project is to test the hypothesis that defective responses to retinoic acid skews the Treg/ TH17 homeostasis in *Sle1a1* mice and identify the mechanisms by which *Pbx1* contributes to the process.

R21 AR052366-01 01/01/05-12/31/08 0.60 calendar months

NIH/NIAMS $300,000

**Role:** Co-Investigator

**Title:** Identifying Gene Interactions in SLE by Mixed Chimeras**.**

Rigel Pharmaceuticals 2007 0.24 calendar months

$50,000

**Role:** Principal Investigator

**Title:** The B6.TC model to investigate to the mechanisms Syk inhibitor protection in lupus.

PO1 AI39824-02 (Wakeland) 4/1/96 - 3/31/01 0.60 calendar months

NIH/NIAMS $2,810,084

**Role:** Co-Investigator

**Title:** Genetic dissection of SLE pathogenesis. Project 1. Genetic dissection of lupus susceptibility using congenic mouse strains.

**Overall Goals:** Project 1 proposing to: 1) To dissect and characterize the genetic mechanisms responsible for the development of murine SLE via the analysis of congenic and polycongenic strains carrying NXM/Aeg2410-derived SLE susceptibility; and 2) To map the positions of epistatic genes in the NZW genome that suppress the express of SLE 1.

PO1 AI39824-02 (Morel) 4/96 - 3/31/01 0.60 calendar months

NIH/NIAMS $2,810,084

**Role:** Principal Investigator

**Title:** Program Projects on Autoimmunity; Project 2. Positional cloning of the SLE genes Sle1, Sle2, and Sle3.

**Overall Goals:** Project 2 proposes to genetically fine-map the position of the 3 Sle loci, and then to identify the corresponding genes, either by candidate gene analysis or conventional positional cloning.

NIMH 59959 (Lenox, Robert H.) 07/1/98 - 6/31/01 0.60 calendar months

**Role**: Co-investigator $747,636

**Title:** Neurobiology of MARCKS: A Macs Mutant Model

**Overall Goals:** This grant proposes to characterize the genetic basis for variations in the expression of Macs.

NIH RFA HL-97-010 (W. Castleman) 0.60 calendar months

**Role:** Co-Investigator $1,125,000

**Title:** Genes controlling virus induced asthma in rats

RO1-NS38179-01 (J. Petitto) 8/1/98 to 7/31/03 1.20 calendar months

National Institutes of Health $784,107

**Role:** Co-investigator

**Title:** IL-2 gene deletion: Neurodevelopment and behavior

**Overall Goals:** This project proposes to characterize the role of IL-2 in neurodevelopment and on behavior by using IL-2 and IL-2R knock-out mice.

R21-ES10277-01 (L. Morel) 10/1/99 to 9/30/02 1.80 calendar months

National Institutes of Health $300,000

RFA ES-99-003 Environment/Infection/Gene Interaction in Autoimmune Diseases

**Role:** Principal Investigator

**Title:** Congenic strains: a model for gene/environment interactions.

**Overall Goals:** This project proposes to use a panel of 17 congenic strains that have been developed at UF to carry defined autoimmune genomic intervals as a tool to assess gene/environment interactions, with an initial focus on estrogen and estrogen-like toxins, and mercury.

RO1-AI45050-01 (L. Morel) 3/1/00 to 2/28/03 3.60 calendar months

National Institutes of Health $539,089

**Role:** Principal Investigator

**Title:** Characterization of SLE-susceptibility loci on mouse chromosome 1

**Overall Goals:** The project proposes to functionally characterize the Sle1 cluster of SLE-susceptibility genes.

RO1-AI43454-01 (E. Sobel) 3/1/00 to 2/28/04 1.80 calendar months

National Institutes of Health $951,652

**Role:** Co-Principal Investigator

**Title:** Functional characterization of loci modifying SLE renal disease

**Overall Goals:** This project proposes to functionally characterize the positive and negative modifiers of Sle1 in the context of renal disease.

PO1-AI39824 (E. K. Wakelan, PD) 6/1/00 to 5/31/04 1.56 calendar months

National Institutes of Health $575,369

**Role:** Principal Investigator of Project 3

**Title:** Genetic dissection of SLE pathogenesis; Project 3: Characterization of SLE-susceptibility loci on mouse chromosome 4

**Overall Goals:** The project proposes to genetically and functionally characterize the Sle2 cluster of SLE-susceptibility genes on chromosome 4.

RPG LBC-1002057/1/01 to 6/31/02 1.80 calendar months

American Cancer Society $248,000

**Role:** Principal Investigator

**Title:** Genetic and functional characterizationof B cell lymphomas in the NZM mouse

**Overall Goals:** The project proposes to genetically and functionally characterize B cell lymphoma susceptibility loci in the NZM mouse using QTL mapping and cDNA arrays

Arthritis Foundation 6/1/02 to 5/31/05 0.24 calendar months

Joseph Craft, M.D., Ph.D. Yale School of Medicine P.I. $90,000

**Role:** Co-Investigator

**Title:** Functional and Genetic Analysis of intrinsic T cell defects in a mouse model of SLE

1PO1 A142288-0, Atkinson (PI) 2001-2006 0.60 calendar months

NIH/NIDDK/NIAI

## **Role:** Co-investigator

**Title:** Immune Function in High and Low Risk Genotypes in IDD

Core B Director Clare-Salzler

**PUBLICATIONS:**

Abstracts:

1. Morel, L. Contribution à l'étude des mouvements antennaires associés aux transferts de nourriture, d'ouvrières à ouvrières, chez la fourmi *Camponotus vagus*. Memoire de DEA, Université Aix-Marseille II, 51 p., 1981.

2. Morel, L. Développement des mouvements antennaires associés aux contacts trophallactiques chez la fourmi *Camponotus vagus* Scop. Bull. Int. SF.UISSI, pp. 100-103, 1981.

3. Morel, L. Variabilité dans le développement des mouvements antennaires associès aux contacts trophallactiques chez la fourmi *Camponotus vagus* Scop. Bull. Int. SFECA, 2:245-251, 1982.

4. Morel, L. Mise en place des processus de régulation du comportement agressif et de la reconnaissance entre ouvrières d'une société de *Camponotus vagus* Scop. Colloq. Int. SF/UISSI, (Eds. A. de Haro and X. Espadaler), Barcelona, Bellaterra, pp. 127-136, 1982.

5. Morel, L. Contribution à l'étude des interactions sociales chez les jeunes ouvrières de la fourmi *Camponotus vagus* Scop.: Développement du comportement trophallactique et régulation de l'agressivite. Thèse de 3ème cycle, Université Aix-Marseille II, 164 p., 1983.

6. Bonavita-Cougourdan, A. and L. Morel. Polyéthisme et comportement de relation. Actes coll. Ins. Soc.,Presses Univ. Paris XII, 1:27-30, 1984.

7. Bonavita-Cougourdan, A. and L. Morel. Variabilité interindividuelle des comportements de relation chez des insectes sociaux. 19th Int'l Ethological Conference, Toulouse, 1:47, 1985.

8. Morel, L. Ontogenèse de la reconnaissance des membres de la société chez la fourmi *Camponotus floridanus* Buckley. Bull. Int. SFECA, 1987.

9. Morel, L. and R.K. Vander Meer. The role of environment-derived cues in nestmate recognition in red carpenter ant workers. Proceedings 4th Internatl. Soc. Chem. Ecol., Hull, England, p.33, 1987.

10. Hauswirth, W.W., L.E. Desjardin, L. Morel and A.M. Timmers. Developmental patterns of bovine retinal gene expression. Invest. Ophthalmol. Vis. Sci., 31:159, 1990.

11. Morel, L., L.R. Herron, B.L. Kotzin, and E.K. Wakeland. Genetic mapping of anti single-stranded DNA antibody production in the NZW mouse. The 6th international mouse genome conference, Buffalo, 1992.

12. Morel, L., U.R. Rudofsky, and E.K. Wakeland. Genetic mapping of glomerulonephritis associated with systemic lupus erythematosus in the mouse. American Association of Immunologists / Clinical Immunology Society meeting, Denver, CO, 1993.

13. Morel, L., U.R. Rudofsky, and E.K. Wakeland. Polygenic control of SLE Susceptibility in the NZM mouse. Experimental Biology '94, Anaheim, CA, 1994.

14. Morel, L., U.R. Rudofsky, and E.K. Wakeland. Polygenic control of lupus nephritis in the NZM mouse. J. Amer. Soc. Nephrol., 5: 759, 1994.

15. Morel, L., U.R. Rudofsky, and E.K. Wakeland. Genetic analysis of systemic lupus erythematosus susceptibility in the NZM mouse. J. Cell. Biochem., suppl. 21A: 149, 1995.

16. Wakeland, E.K., Morel, L., Mohan, C., and U.R. Rudofsky. Genetic analysis of systemic lupus erythematosus susceptibility in the NZM mouse. The 9th International Congress of Immunology, San Francisco, CA, 1995.

17. Morel, L., Mohan, C., Croker, B.P., Tian, X.-H., Wakeland, E.K. Antinuclear autoantibody production mediated by a single murine lupus erythematosus susceptibility locus. Keystone symposium, 1996.

18. Mohan, C., Morel, L., Croker, B.P., Wakeland, E.K. A lupus susceptibility interval on chromosome 4 dictates B-cell hyperactivity. Keystone symposium, 1996.

19. Morel, L., Schiffenbauer, J., Rudofsky, U.H., Longmate, J.A., Mohan, C., Sobel, E., Wakeland, E.K. Complex inheritance of component phenotypes in a murine model of SLE. 10th international Mouse Genome Conference, 1996.

20. Mohan, C., Alas. E., Morel, L., Yang, P. And Wakeland, E.K. Genetic dissection of SLE pathogenesis: *Sle1* on chromosome 1 leads to loss of tolerance to H2A/2B/DNA subnucleosomes. ACR 60th scientifict meeting, Orlando, Fl., 1996.

21. Vyse, T.J., Morel, L., Tanner,F.J., Wakeland, E.K., Kotzin, B.L. Backcross analysis of genes linked to autoantibody production in New Zealand White mice. ACR 60th scientifict meeting, Orlando, Fl., 1996.

22. Morel, L., Mohan, C., Yu, Y., Croker, B.P., Wakeland, E.K. Functional dissection of SLE using congenic mouse strains. Arthritis Research Conference, NIH, May29-June 1, 1997.

23. Mohan, C.,Morel, L., Yu, Y., Croker, B.P., Wakeland, E.K. Genetic dissection of SLE pathogenesis using congenic mouse strains. FASEB Summer Research Conference, 1997.

24. Morel, L., Mohan, C., Yu, Y., Croker, B.P., Wakeland, E.K. Genetic dissection of SLE in the NZM2410 model: evidence for NZW epistasis controlling anti-chromatin antibodies and glomerulonephritis. FASEB Summer Research Conference, 1997.

25. Morel, L., Croker, B.P., Blenman, K.B., and Wakeland, E.K. A major negative modifier is linked to the MHC *H2z* allele in murine lupus. 11th Mouse Genome Conference, St. Petersburg, 1997.

26. McNamara, R.K., Stumpo, D.J., Lewis, M.H., Morel, L., Wakeland, E.K., Blackshear, P.J., Lenox, R.H. Hyppocampal Marcks expression is inversely correlated with spatial learning ability and infrapyramidal mossy fiber size in inbred and mutant mice. Society for Neurosciences, 1997.

27. Morel, L., Mohan, C., Croker, B.P., Sobel, E. Wakeland, E.K. *Sle1* on murine chromosome 1 is a key SLE-susceptibility locus. Experimental Biology ‘98, San Francisco, 1998.

28. Mohan, C.,Morel, L., Kontaridis, M., Yang, P., Wakeland, E.K. Genetic dissection of SLE pathogenesis: *Sle3* potentiates *Sle1*-induced autoimmunity. Experimental Biology ‘98, San Francisco, 1998.

29. Yu, Y., Morel, L., Mohan, C., Croker, B.P., Wakeland, E.K. Functional analysis of SLE susceptibility in B6.NZMc7 congenic mice. Experimental Biology ‘98, San Francisco, 1998.

30. B. Croker, L. Morel, C. Mohan, and E.K. Wakeland. Glomerulonephritis (GN), proteinuria and pathogenesis of murine lupus nephritis. American Society of Nephrology, Philadelphia, 1998.

31. Morel, L., J. Tulsian, and E.K. Wakeland. Genetic analysis of SLE gender bias using congenic mouse strains. Linking environmental agents and autoimmune diseases, NIEHS Workshop, Research Triangle Park, 1998.

32. Morel, L., B.P. Croker, K.R. Blenman, and E.K. Wakeland. Genetic and functional characterization of the cluster of SLE-susceptibility loci on mouse telomeric chromosome 1. FASEB Summer Research Conference, 1999.

33. Morel, L., B.P. Croker, K.R. Blenman, and E.K. Wakeland. Genetic and functional characterization of the cluster of SLE-susceptibility loci on mouse telomeric chromosome 1. Arthritis research Conference, Alexandria, VA, 1999.

34. McNamara, R.K., D.J. Stumpo, M.H. Lewis, L.Morel, P.J. Blackshear, and R.H. Lenox Effect of Reduced MARCKS Expression on Hippocampal Mossy Fiber Development and Spatial Learning in Mutant Mice: Transgenic Rescue and Interactions with Gene Background. Society for Neurosciences, 1999.

35. Jones, H.C., B.A. Lopman, T.W. Jones, J. S. Depelteau, B.J. Carter, and L. Morel. Characteristics and genetic analysis of hydrocephalus in the H‑TX rat strain. Society for Neurosciences, 1999.

36. Morel, L., B.P. Croker, K.R. Blenman, and E.K. Wakeland. Stepwise reconstitution of SLE-susceptibility in polycongenic B.NZM strains. The 13th International Mouse Genome Conference, Philadelphia, PA, 1999.

37. Chu, C.C., S.S. Chavan, M. Naidu, L. Morel, E.K. Wakeland, and K. Hsueh. *Fig1* in systemic lupus erythematosus. Experimental Biology ‘99, Washington, DC, 1999.

38. Sobel, E.S., L. Morel, J. Schiffenbauer, R. Baert, C. Mohan, and E.K. Wakeland. Adoptive transfer of NZM-derived lupus susceptibility locus *Sle3/5* on murine chromosome 7 by bone marrow. American College of Rheumatology meeting, Boston, Ma, 1999.

39. Croker, B.P., L. Morel, C. Mohan, and E.K. Wakeland. Congenic dissection and reconstitution of murine lupus nephritis. J. Am. Soc. Nephrol., 10: SU619, 1999.

40. Croker, B.P., L. Morel, and E.K. Wakeland. Genetic dissection and reconstitution of glomerulonephritis (GN) in mice with systemic lupus erythematosus (SLE). USCAP meeting.

41. Hori, M., C.‑F. Qi, T.A. Torrey, N.A. Jenkins, N.G. Copeland, L. Morel and H. C. Morse III, 2000. Analysis of mouse splenic marginal zone lymphomas for mutations of *p53*. AACR meeting, 2000.

1. Morel, L., Croker, B.P., and E.K. Wakeland. Genetic reconstitution of systemic lupus erythematosus immunopathology with poly-congenic murine strains. Keystone Symposium, Steamboat, CO, 3/31-4/6 2000.
2. Sobel, E.S., L. Morel,J.Schiffenbauer, R. Baert, C. Mohan and E.K. Wakeland Adoptive transfer of lupus susceptibility locus *Sle2* on murine chromosome 4. American College of Rheumatology meeting, Philadelphia, Pa, 2000.
3. Morel, L. and E.S. Sobel. Independent expression of murine SLE-susceptibility locus *Sle1* in B and T cells indicates intrinsic defects in both compartments. American College of Rheumatology meeting, Philadelphia, Pa, 2000.
4. Croker, B.P. and L. Morel. Congenic reconstitution of murine lupus nephritis: demonstration of parallel genetic pathways. International Association of Pathologists meeting, Nagoya, Japan 2000.
5. Blenman, K.R.M., L. Moldawer, and L. Morel. Analysis of proinflammatory defects in the SLE-prone NZM2410 mouse, using an endotoxemic shock (ETS) model. FASEB 2001, Orlando, Fl.
6. Boackle, S.A., V.M. Holers, D.R. Karp, E.K. Wakeland, and L. Morel. Cr2, a Candidate Gene for the *Sle1c* Lupus Susceptibility Locus, Encodes a Dysfunctional Protein in the NZM2410 mouse. FASEB 2001, Orlando, Fl.
7. Morel, L., E. Basco, and B.P. Croker. Functional Differences Between the *Sle1* Loci Revealed through Their Interactions With Other SLE Susceptibility Genes. FASEB 2001, Orlando, Fl.
8. Morel, L., and B.P. Croker. Relationship between aberrant marginal zone B cell development and autoimmunity in the NZM murine model of systemic lupus erythematosus. Keystone Symposium, Snowbird, UT, 3/31-4/6 2001.
9. H.C. Jones, B.J. Carter, J. S. Depelteau, and L. Morel. The severity of hydrocephalus is influenced by different genetic loci. Society for Research into Hydrocephalus and Spina Bifida, Upsala, Sweden, 6/27-6/30 2001.
10. Croker, B.P. and L. Morel. Lupus nephritis loci overwhelm C57BL/6 resistance to nephropathy. ASN/ISN world congress of nephrology, San Francisco, CA, 10/14 – 10/17 2001.
11. Morel, L., K.R. Blenman, B.P. Croker, and E. S. Sobel. Functional and genetic characterization of *Sle1*, a major susceptibility locus in murine systemic lupus erythematosus. American College of Rheumatology meeting, San Francisco, Ca, 2001.
12. Morel, L., and B.P. Croker**.** B cell developmental pathways correlate with clinical outcomes in the NZM murine model of systemic lupus erythematosus**.** American College of Rheumatology meeting, San Fransisco, Ca, 2001.
13. Blenman, K.R.M., Moldawer, L., and Morel, L. Mapping defects in the TFNalpha functional pathway in the SLE-prone NZM2410 mouse. American College of Rheumatology meeting, San Francisco, Ca, 2001.Sobel, E.S.
14. Boackle, S.A., Holers, V.M., Chen, X., Szakonyi, G., Karp, D.R., Wakeland, E.K., and Morel, L. *Cr2*, a Candidate Gene in the *Sle1c* Lupus Susceptibility Locus, Encodes a Dysfunctional Protein in the NZM2410 mouse. American College of Rheumatology meeting, San Francisco, Ca, 2001.
15. Sobel, E.S., Baert, R., Butfiloski, E.J., J., and Morel, L. Interactions between NZM-derived Sle1 and Sle3/5 lupus susceptibility loci in the generation of elevated CD4:CD8 ratios in mixed chimeras. American College of Rheumatology meeting, San Francisco, Ca, 2001.
16. Jones, H.C., B.Yehia, B.J. Carter, J.S. Depelteau, and L.Morel. Complex genetic and maternal effects in early-onset rat hydrocephalus. Physiological Genomics and Rat Models, Cold Spring Harbor, 2001.
17. Morel, L. and B.P. Croker, Interactions between the *Sle1* loci and other SLE-susceptibility loci model the complex synergism that creates SLE pathogenesis. Keystone Symposium, Steamboat, CO, 4/1/-4/7 2002.
18. Wandstrat, A.E., Nguyen, C., Limaye, N., Morel, L., Wakeland, E.K. Identification of Sle1b as a Member of the CD2 Ig superfamily. FASEB 2002, New Orleans, LA.
19. Morel, L., and Croker, B.P. Genetic and functional characterization of B cell lymphomas in the NZM mouse. Int. Cancer Conference, June 30 - July 6 2002, Oslo, Norway.
20. Carter, B.J., Morel, L., and Jones, H.C. LEW/Jms Rat: Hydrocephalus Expression and Inheritance. Society for Research into Hydrocephalus & Spina Bifida 46th Annual Scientific Meeting 10 - 13 July 2002 Leuven, Belgium
21. Croker, B.P., Morel, L., Morse, H.C.III, Ward, J.M. Systemic lupus erythematosus (SLE) associated lymphomas and autoimmunity in B6.NZM SLE1|2|3 (NZM) and TAN mice. International Assoc. Pathologists, Oct. 5-10, 2002, Amsterdam, The Netherlands.
22. Croker, B.P., and Morel, L., Functional dissection, epistasis and glomerulonephritis among systemic lupus erythematosus (SLE) genetic loci. ASN renal Week, Nov. 1 – 4, 2002, Philadelphia, PA.
23. Sobel, E.S., Butfiloski, E.J., and Morel, L. Epistasis between Sle1 and Yaa requires interactions within the B cell compartment. American College of Rheumatology meeting, New Orleans, LA, 2002.
24. Chen, Y, and Morel, L. T cell hyperproliferation and activation map to Sle1a and Sle1c. AAI, May 6-10, 2003 Denver, CO. FASEB J., 17: C181, 2003.
25. Blenman, K.R.M, and Morel, L. Gene therapy in lupus mice. AAI, May 6-10, 2003 Denver, CO. FASEB J., 17: C271, 2003.
26. Morel. L., Croker, B.P. and Morse, H.C.III. B cell developmental defects correlate with lupus pathogenesis in the NZM model AAI, May 6-10, 2003 Denver, CO. FASEB J., 17: C182, 2003.
27. Boackle, S.A., Tchepeleva, S.N., Kachinski, J.J., Giles, B.M., Kenyon, K.D., Karp, D.R., and Morel, L. Functional effects of a single nucleotide polymoprhism in the Sle1c allele of Cr2. AAI, May 6-10, 2003 Denver, CO. FASEB J., 17: C181, 2003.
28. Morel, L., Blenman, K.R.M., Duan B., Croker, B.P., and Sobel, E.S. Divergent effects of Th1 and Th2 cytokines in a mouse model of SLE. American College of Rheumatology meeting, Orlando, Fl, 2003.
29. Chen, Y., Perry D., Boackle S.A., Sobel, E.S. and Morel, L. Effects of the lupus susceptibility locus Sle1c and its candidate gene Cr2 on B and T cell functions. American College of Rheumatology meeting, Orlando, Fl, 2003.
30. Duan, B. Croker, B.P., Sobel, E.S. and Morel, L. B cell developmental defects correlate with presence or absence of autoimmune pathology in the NZM strains. American College of Rheumatology meeting, Orlando, Fl, 2003.
31. Boackle, S.A.,Ulgiati, D., Holers, M.V., Kaufman, K.M., Harley, J. Is CR2 a Human Lupus Susceptibility Gene? Sequencing Analysis of Multiplex Families. Lupus Research Institute Annual Meeting, New York City, NY, September 2003.
32. Croker, B.P. She, J.X., Madsen, K.S., Agrawal, A., and Morel, L. Treatment of NON Mice by Protein Overload. ASN renal Week, Nov. 1 – 4, 2003, San Diego, CA.
33. Yin, Z., Pan, M. You, Xi. Zhoa, H., and Morel, L. Identification of novel susceptibility loci of collagen-induced arthritis using different H-2 haplotype intercrossing. FASEB mtg. 2004
34. Morel, L., Xu, Z., Duan, B. and Sobel, E. Genetic and Functional Mechanisms of Peritoneal B1a Accumulation in Lupus Mice. 12th International Congress of Immunology, Montreal, Canada, 2004.
35. Boackle, S.A., Giles, B.M., and Morel, L. Epistatic effects of the *Sle1c* lupus susceptibility interval on NZB autoimmune phenotypes, XXth International Complement Workshop, Hawai, 2004.
36. Boackle, S.A., Giles, B.M., Kachinski, J.J., Croker, B.P., and Morel, L. Epistatic effects of the *Sle1c* lupus susceptibility interval on NZB autoimmune phenotypes. Second International Conference on B cells & Autoimmunity: New concepts & therapeutic perspectives” 15th – 18th July 2004, Quebec City, Quebec, Canada.
37. Duan, B. Erickson, E., Croker, B. P., and Morel, L. Splenic accumulation of plasma cells correlates with clinical disease in murine models of lupus. Second International Conference on ”B cells & Autoimmunity: New concepts & therapeutic perspectives” 15th – 18th July 2004, Quebec City, Quebec, Canada.
38. Su, L., Morel, L., Hsu, Y-M., Burkly, L., Michaelson, J. Putterman, C. Lupus-prone mice display high levels of circulating TNF-like weak inducer of apoptosis (TWEAK, TNFSF12). American College of Rheumatology meeting, San Antonio, Tx, October 18-22, 2004.
39. Duan, B., Croker, B.P., and Morel, L. Abnormal B-cell phenotypes and follicle architecture correlate with lupus in NZM strains. Experimental Biology 2005, San Diego, CA, April 2-6, 2005.
40. Morel, L., Xu, Z., Sobel. E.S., Corker, B.P. Peritoneal B-1a cell accumulation: analysis of its contribution to systemic lupus erythematosus (SLE) and genetic mapping within the *Sle2* locus. B cells Keystone Symposia, Steamboat, Co. March 28 – April 03, 2005.
41. Morel, L. Genetics of murine lupus. 2nd Conference on Autoimmunity: Mechanisms and Novel Treatments, Santorini, Greece, Sept. 25-28, 2005.
42. Morel, L. Genetics of murine lupus. 9th IWAA, Gainesville, Fl, Sept. 29 – Oct. 2, 2005.
43. Duan, B., Croker, B.P., and Morel, L. Marginal zone B cells localization inside the follicle correlates with anti-nuclear autoantibody production in the NZM2410 lupus model. 9th IWAA, Gainesville, Fl, Sept. 29 – Oct. 2, 2005.
44. Wan, S., Xu, Z., Duan, B., Cuda, C., Croker, B.P., Morel, L. B7-2/CD86, but not B7-1/CD80 deficiency completely prevents anti-nuclear autoantibody production and clinical disease in the NZM2410 lupus model. 9th IWAA, Gainesville, Fl, Sept. 29 – Oct. 2, 2005.
45. Cuda, C., Chen, Y., Morel, L. Role of autoreactive T-cells in the production of anti-nuclear autoantibodies in the NZM 2410 lupus model. 9th IWAA, Gainesville, Fl, Sept. 29 – Oct. 2, 2005.
46. Xu, Z., Duan, B., Croker, B.P., Morel, L. Both STAT4 and STAT6 deficiency abrogate anti-nuclear autoantibody production, but only STAT4 affects clinical disease in the NZM2410 lupus model. 9th IWAA, Gainesville, Fl, Sept. 29 – Oct. 2, 2005.
47. Duan, B., Morel, L.B-cell responses to BCR stimulation correlate with lupus susceptibility and resistance in NZM mouse strains. AAI meeting, Boston, MA, May 12-16, 2006.
48. Xu, Z., Morel, L. The Sle2 Lupus Susceptibility Locus Inhibits Chronic Graft versus Host Reaction. AAI meeting, Boston, MA, May 12-16, 2006.
49. Cuda, C. M., Chen, Y., Morel, L. Influence of *Sle1a* lupus susceptibility locus on CD4+CD25+CD62L+ regulatory T-cell levels in the NZM 2410 lupus model. AAI meeting, Boston, MA, May 12-16, 2006.
50. Cuda, C. M., Chen, Y., Morel, L. Expression of Sle1a is required for T cell intrinsic phenotypes. American College of Rheumatology Annual Scientific Meeting, Washington, D.C., Nov. 11-15, 2006.
51. Niu, H.N., and Morel, L. Defective response to T-dependent immunization in lupus-prone mice. American College of Rheumatology Annual Scientific Meeting, Washington, D.C., Nov. 11-15, 2006.
52. Wan, S., Yang, L.-J., and Morel, L. Enhanced IL−6 production by bone marrow derived dendritic cells from lupus−prone mice Inhibits CD4+CD25+ T cell mediated suppression. American Society of Hematology Annual Scientific Meeting, Orlando, Fl, Dec. 9-12, 2006.
53. Xu, Z. and Morel, L. Multi-positions in the Sle2 locus derived from lupus NZM2410 mouse inhibit chronic graft versus host reaction. 8th International Congress on SLE, Shangai, China, May 23-27, 2007.
54. Niu, H.N., and Morel, L. Intrinsic B cell defect results in abnormal TD antigen response in lupus-prone mice. AAI meeting, Miami, FL, May 18-22, 2007.
55. Cuda, C.M., and Morel, L. Functional analysis of regulatory T cells in a murine model of lupus. AAI meeting, Miami, FL, May 18-22, 2007.
56. Perry, D., and Morel, L. Genetic analysis of the Sle1c lupus susceptibility locus. AAI meeting, Miami, FL, May 18-22, 2007.
57. Pinedo, P.J., Buergelt, C.D., Wu, R., Donovan, G.A., Williams, J.E., Melendez, P.G., Morel, L. and Rae, D.O. Association between Two Polymorphisms in the Bovine CARD15/NOD2 Gene and Paratuberculosis Infection in Florida Dairy and Beef Cattle. International Colloquium on Paratuberculosis, Tsukuba, Japan, Oct. 26-29, 2007.
58. Cuda, C.M., and Morel, L. Expression of *Sle1a* is required for observed T cell-intrinsic phenotypes. Florida Genetics Symposium, University of Florida, Nov 14, 2007.
59. Perry, D. and Morel, L. Florida Genetics Symposium, University of Florida, Nov 14, 2007.
60. Niu, H.N., Shlomchik, M., and Morel, L. AM14 B cells breach tolerance and bypass GC reaction in the NZM2410 lupus model. Tolerance in transplantation and autoimmunity, Keystone symposium, Jan. 29- Feb. 2, 2008.
61. Cuda, C.M., Dozmorov, I., and Morel, L. Lupus susceptibility locus *Sle1a(15)* contains a gene that controls Treg levels in the periphery. Tolerance in transplantation and autoimmunity, Keystone symposium, Jan. 29- Feb. 2, 2008.
62. Perry, D., Boackle, S.A., and Morel, L. [Genetic](http://schemas.microsoft.com/office/word/2003/wordml) dissection of the lupus susceptibility locus, *Sle1c.* Tolerance in transplantation and autoimmunity. Regulatory T cell Keystone Symposium, Jan. 29- Feb. 2, 2008.
63. Perry, D., Dozmorov, I., Morel, L. Treg/Th17 homeostasis is altered by a gene in the lupus susceptibility locus, Sle1c-2. 2008 Lupus Genetics Conference. Oklahoma City, OK. Oct. 10 – 14, 2008. (oral presentation)
64. Perry, D., Dozmorov, I., Morel, L. Refinement of the lupus susceptibility locus, Sle1c. Florida Genetics 2008. Gainesville, FL. Oct. 29 - 30, 2008.
65. Cuda, C.M., Dozmorov, I., Morel, L. A gene within lupus susceptibility locus *Sle1a.1* controls Tregs levels in the periphery. Florida Genetics 2008. Gainesville, FL. Oct. 29 - 30, 2008.
66. Perry, D., Dozmorov, I., Morel, L. Treg/Th17 homeostasis is altered by a gene in the lupus susceptibility locus, Sle1c-2. Keystone Symposia 2009. TH17 Cells in Health and Disease. Vancouver, BC Feb 5 – 9, 2009.
67. Niu, H.N., Zhou, Z., Sobel, E.S., Shlomchik, M., and Morel, L. Rheumatoid factor autoimmunity in the NZM2410 model combines antigen-specific and polyclonal activation. AAI meeting, Seattle, WA, May 8-12, 2009.
68. Xu, Z., Croker, B.P., and Morel, L. The *Sle2c1* murine susceptibility locus controls T cell homeostasis through defective IL-2 production. AAI meeting, Seattle, WA, May 8-12, 2009.
69. Cuda, C.M., Li, S., Dozmorov, I., Morel, L. Pbx1 plays a role in controlling the level of Tregs in the periphery.Regulatory T cell Keystone Symposium, Keystone, CO, March 1- 6, 2009.
70. Sobel, E.S., Butfiloski, E., Cuda, C.M., and Morel, L. Defective Retinoic Acid expansion of Foxp3+ regulatory CD4+ T cells in lupus patients. Focis 2009, San Francisco, CA, June 11-14, 2009.
71. Xu, Z., and Morel, L. Murine *Sle2c1* sublocus synergizes with *lpr* mutation in contributing to lupus nephritis. American College of Rheumatology Annual Scientific Meeting, Philadelphia, PA, Oct. 17-21, 2009.
72. Dugan, A. and Morel L. The influence of prolactin on the inflammatory component of lupus nephritis. AAI meeting, Baltimore, MD, May 7-11, 2010.
73. Garrigan, E., Han, Z., Seydel, F., Belkin, N., Riggs, C., Amick, M., Cdebaca, A., Pilant, T., Bober, R., Wasserfall, C.,Atkinson, M., Clare-Salzler, M.J., Morel, L., McDuffie, M., and Litherland, S.A. A model for studying the impact of nurture on nature: Development of diabetes in multicongenic mice with an epigenetic gene expression dysregulation defect from the nonobese diabetic mouse (NOD). ADA conference, Orlando, Fl., June 26-28, 2010.
74. Niu, H., Xie, L., Morel, L., Diamond, B., and Zou, Y-R. Dysfunction of Hematopoietic Stem Cells in Lupus Mice. ACR 2010, Atlanta, GA, October, 2010.
75. Xu, Z., and Morel, L. *Sle2c2* sublocus, derived from murine lupus susceptibility *Sle2* locus, suppresses chronic graft versus host reaction in late phase. Cold spring harbor Asia conference on Frontiers of Immunology in Health and Diseases, Suzhou, China, November 7 - 10, 2010.
76. Sang, A., Morel, L. Antigen Specific and Non-Specific Activation of Rheumatoid Factor B-cells in the Triple Congenic Mouse Model of Lupus. Keystone Symposia Conference: B-cells: New Insights into Normal versus Dysregulated Function, Whistler, CA, April 12-17, 2011.
77. Xu, Z., Potula, H.H.S.K., Vallurupalli, A., Morel, L. Reduced expression of cyclin-depedent kinase inhibitor *Cdkn2c* decreases IL-2 Production by CD4+ T cells expressing the murine NZB-derived *Sle2c1* susceptibility locus. AAI meeting, San Francisco, CA, May 14-17, 2011.
78. Potula, H.H.S.K.., Xu, Z., Morel, L.Expansion of peritoneal B1a cells in NZM2410 lupus-prone mice is regulated by the cell cycle regulator gene *Cdkn2c.*AAI meeting, San Francisco, CA, May 14-17, 2011.
79. Sobel, E.S., Butfiloski, E., Hunt, J., Segal, M., Morel, L., Reeves, W.H., Satoh, M. A Novel Circulating CXCR5-CD20++ B Cell Compartment in Patients with Systemic Lupus Erythematosus. ACR 2011, Chicago, IL, November 4—9, 2011.
80. Sang, A., Morel, L. Mechanisms for non-antigen specific rheumatoid factor B cell activation in the NZM2410 Mouse Model of Lupus. AAI meeting, Boston, MA, May 4-8, 2012.
81. Zheng, Y.-Y., Morel, L. Marginal zone B cells contribute to autoimmunity in the NZM2410 lupus prone mouse model.AAI meeting, Boston, MA, May 4-8, 2012.
82. Xu, Z, Morel, L. The lupus-susceptibility *Sle2c1* sublocus regulates T cell expansion through several mechanisms. AAI meeting, Boston, MA, May 4-8, 2012.
83. Sengupta, M., Liang, S., Morel, L. Pre-B Cell Leukemia Homeobox 1 is a novel susceptibility gene that regulates T cell functions. AAI meeting, Boston, MA, May 4-8, 2012.
84. Potula, H.H.S.K., Xu, Z., Morel, L. B1a cell expansion and autoimmunity promoted by Cyclin-dependent kinase inhibitor *Cdkn2c* deficiency in a mouse model of lupus. AAI meeting, Boston, MA, May 4-8, 2012.
85. Yin, Y., Perry, D., Perl, P., Morel, L. Regulation of T cell metabolism and autoimmunity by the orphan nuclear receptor ERRγ. AAI meeting, Boston, MA, May 4-8, 2012.
86. Sang, A., Morel, L. Mechanisms for non-antigen specific rheumatoid factor B cell activation in the NZM2410 Mouse Model of Lupus. Henry Kunkel Society meeting, Berlin, Germany, June 6-10, 2012.
87. Zheng, Y.-Y., Morel, L. Marginal zone B cells contribute to autoimmunity in the NZM2410 lupus prone mouse model.Henry Kunkel Society meeting, Berlin, Germany, June 6-10, 2012.
88. Ying, Y., Perry, D., Mathews, C., Morel, L. Contribution of Estrogen Related Receptor Gamma (*Esrrg*) to Abnormal T Cell Metabolism in a mouse model of SLE. Keystone Symposia: Metabolic Control of Inflammation and Immunity, Breckenridge, Colorado, January 2013.
89. Sang A, and Morel L. Multistep Regulation of Rheumatoid Factor B Cell Activation in the NZM2410 Mouse Model of Lupus*.* Abstract submitted for poster presentation. Keystone Symposia: B cell Development and Function, Keystone, Colorado, February 2013.
90. Xu Z. and Morel L. A short murine lupus-susceptibility Sle2c1rec1sublocus functions as both contributor and modifier of autoimmune disease in CD95 deficiency. AAI meeting, Honolulu, HI, 2013.
91. Zheng, Y.-Y., Morel, L. Contribution of marginal zone B cells to autoimmunity in the B6.Sle1.Sle2.Sle3 lupus prone mouse model. UAB 2013 Spring Immunology Symposium, Birmingham, AL., June 22-23, 2013.
92. Zheng, Y.-Y., Morel, L. Contribution of Marginal Zone B cells to Autoimmunity in the B6.Sle1.Sle2.Sle3 Lupus Prone Mouse. ACR meeting, San Diego, CA, Oct. 26-30, 2013.
93. Sivakumar, R., Morel, L. Characterizing the role of the granulocyte colony stimulating factor pathway in a mouse model of systemic lupus erythematosus. American College of Rheumatology meeting, San Diego, CA, Oct. 26-30, 2013.
94. Choi, S.C., Zeumer, L., and Morel, L. Overexpression of Pbx1-d, a novel splice isoform of Pbx1, changes the portion of follicular CD4 T cell populations and impairs regulatory T cell homeostasis, AAI meeting, Pittsburg, PA, 2014.
95. Yiming, Y., Brusko, T., Mathews, C., Sobel, E., and Morel, L. Metabolic inhibitors normalize CD4 T cell metabolism and functions, and reverse disease in a murine model of lupus. AAI meeting, Pittsburg, PA, 2014.
96. Choi, S.C., Zeumer, L., and Morel, L. MicroRNAs regulation of effector T cell differentiation in Pbx1-d-transgenic CD4 T cells. Immunogenomics 2014 Conference, Hunstville, AL, September 29-October 1, 2014.
97. Titov, A., Niu, Y, Yin, Y., and Morel, L. Characterization of Pbx1 binding to Esrrγ genomic sites. Florida Genetics symposium, Gainesville, Fl., Oct. 29-30, 2014.
98. Choi, S.C., and Morel, L. MicroRNAs regulation of effector T cell differentiation in Pbx1-d-transgenic CD4 T cells. Florida Genetics symposium, Gainesville, Fl., Oct. 29-30, 2014.
99. Yin, Y., Choi, S.C., Croker, B.P., Sobel, E., and Morel, L. The combination of metformin and 2-Deoxy-D-Glucose normalizes lupus CD4 T cell metabolism and functions, and reverses disease in murine models of lupus. American College of Rheumatology meeting, Boston, MA, Nov. 15-18, 2014.
100. Mountz, J.D., Li, H., Fu, Y.-X., Zhou, Y., Crossman, D.K., Wu, Q., Yang, P.A., Li, J., Luo, B., **Morel, L.,** Kabarowski, J.H., Yagita, H., Ware, C., and.\ Hsu, H-C. Type I interferons promote lupus through disruption of the lymphotoxin receptor mediated mechanosensing MKL1 pathway in marginal zone macrophages. AAI meeting, New-Orleans, LA, 2015. (oral presentation)
101. Choi, S.C. and **Morel, L**. Overexpression of *Pbx1-d*, a novel splice isoform of *Pbx1*, in CD4+ T cells promotes follicular helper T cell differentiation. AAI meeting, New-Orleans, LA, 2015. (oral presentation)
102. **Morel, L**., Lu, S., Zeumer, L., Sorensen, H., Riva, A., Croker, B.P., and Wallet, S**.** The murine Pbx1-d lupus susceptibility allele accelerates mesenchymal stem cell differentiation and impairs their immunosuppressive function. AAI meeting, New-Orleans, LA, 2015.
103. Yin, Y. Choi, S.C., Xu, Z., Perry, D.J., Seay, H., Croker, B.P., Sobel, E.S., Brusko, T.M., and **Morel, L**. Normalization of CD4+ T Cell Metabolism Reverses Lupus. Mitochondria Cell Symposium, Chicago, IL, July 19-20, 2015.
104. Croker, B. P., Roopenian, D.C., and **Morel, L**. Prevention of Lupus Nephritis in the BXSB-Yaa Mouse by Metabolic Inhibitors. ASN Kidney week, San Diego, CA, Nov. 3-8, 2015.
105. Choi, S.C., Xu, Z., Adkins, E., Croker, B.P., Roopenian, D. C., and **Morel, L**. Therapeutic targeting of CD4+ T Cell Metabolism in Murine Models of Lupus. American College of Rheumatology meeting, San Francisco, CA, November 6-11, 2015 (oral presentation).
106. Sivakumar, R. and **Morel, L**. Characterizing the effects of the G-CSF-R coding rs13377964 SNP located within murine lupus susceptibility locus*Sle2c2*. American College of Rheumatology meeting, San Francisco, CA, November 6-11, 2015 (oral presentation).
107. Yin Y., Choi S.C., Croker B.P., Sobel E.S., Brusko T.M., and **Morel L**. Targeting CD4+ T cell metabolism in lupus. Keystone Symposium: Immunometabolism in Immune Function and Inflammatory Disease., Feb, 21-25, 2016 (oral presentation).
108. Choi S.C., Hutchinson, T.E., Titov, A.A., Seay, H., Li, S., Brusko, T.M., Croker, B.P., Salek-Ardakani, S., and **Morel L.** The lupus susceptibility gene *Pbx1* regulates the balance between follicular helper T cell and regulatory T cell differentiation. Keystone Symposium: T Follicular Helper Cells and Germinal Centers, Feb, 26-March 1, 2016 (oral presentation).
109. Titov, A., Brusko, T. Sobel, E., Baker, H. and **Morel, L**. MDM2 ubiquitin ligase in Lupus CD4 T-Cell pathology. AAI 2016, Seattle, WA,
110. Choi, S.C., Zeumer, L., Yin, Y. and **Morel, L**. Metabolic inhibitors eliminate the expansion of autoimmune follicular helper T cells but not that induced by T-dependent-immunization in lupus mice AAI 2016, Seattle, WA (oral presentation).
111. Perry, D.J., Yin, Y., **Morel, L.,** and Brusko, T.M. Metabolic profiling of human PBMC subsets, Society of Leukocyte Biology at AAI 2016, Seattle, WA (oral presentation).
112. Elshikha, A.S., Lu, A., Chen, M.-J., Akbar, M., Zeumer, L., Yuan, Y., **Morel, L**., and Song, S. Alpha 1 antitrypsin protein and gene therapies for the treatment of lupus in animal models. ASGCT 2016, Washington, D.C., May 4-7, 2016.
113. Thomas J Sproule, John Wilson, Elisabeth Adkins, Byron P Crocker, Laurence Morel, Derry C Roopenian. Metabolic inhibition by 2-deoxyglucose prevents and reverses lupus in mice. *L*upus Sci Med *2016;3:Suppl 1 A10 doi:10.1136/lupus-2016-000179.19*
114. Margaret O. James, Andrew S. Kane, Joan Flocks, Jeannie Economos, Makyba Charles, Patricia Weinstein, Cassandra Brown, Viet Dang, Matthew Booth, Stephen M. Roberts, Eric Sobel, **Laurence Morel** and Nancy D. Denslow. Serum 1,1-dichloro-2,2 bis(4-chlorophenyl) ethane (p,p'-DDE) concentrations in former farmworkers from the Lake Apopka region of Central Florida**. Environmental Health Science Fest for NIEHS Grantees, Durham, NC. Dec. 5-8, 2016.**
115. Margaret O. James, Andrew S. Kane, Joan Flocks, Jeannie Economos, Makyba Charles, Patricia Weinstein, Cassandra Brown, Viet Dang, Matthew Booth, Stephen M. Roberts, Eric Sobel, **Laurence Morel** and Nancy D. Denslow. Serum 1,1-dichloro-2,2 bis(4-chlorophenyl) ethane (p,p'-DDE) concentrations and the prevalence of serum anti-nuclear autoantibodies in former farmworkers from the Lake Apopka region of Central Florida**.** Society of Toxicology Annual Meeting, Baltimore, MD, March 12-16, 2017.
116. Choi, S.C., Titov, A.A., and **Morel, L**. Autoreactive follicular helper T cells are sensitive to glycolysis inhibition but antigen-specific follicular helper T cells are not. Keystone Symposium: B cells & T Follicular Helper Cells Controlling Long-Lived Immunity. April 23-27, 2017.
117. Choi, S.C., Abboud, G., Titov, A.A., and **Morel, L**. Unique requirement of high levels of glucose metabolism by autoreactive follicular helper T cells**.** Keystone Symposium: Integrating Metabolism and Immunity. May 29-June 2, 2017. (oral presentation).
118. Choi, S.C., Mohamadzadeh, M., and **Morel, L**. Gut dysbiosis contributes to autoimmune pathogenesis in lupus-prone mice. AAI 2017, Washington, D.C. (oral presentation).
119. Titov, A.A, Brusko, T. Sobel, E., Baker, H. and **Morel, L**. Metformin attenuates the Type I Interferon response in human peripheral blood leukocytes. AAI 2017, Washington, D.C. (oral presentation).
120. Robusto, B, Zeumer, L., and **Morel, L.** Effect of the Expression of the Lupus Associated Pbx1-d Isoform on Mesenchymal Stem Cells (MSCs) in a Mouse Model of Lupus ASM Annual biomedical research Conference for minority students, Phoenix, AZ, Nov. 2-4, 2017.
121. Choi, S.C., Abboud, G., Titov, A.A., and **Morel, L.** Targeting follicular helper CD4 T cells in SLE. LRA Forum for Discovery, New York, NY, Oct. 23-24, 2017.
122. Choi, S.C., Brown, J., Mohamadzadeh, M., Croker, B. J., and **Morel, L**. Gut dysbiosis contributes to autoimmune pathogenesis in lupus-prone mice. ACR 2017, San Diego, CA., Nov. 4-9, 2017 (oral presentation).
123. Elshikha A., Y Yuan, Y Lu, M Chen, M Akbar, H Plate, L Zeumer, **L Morel**, S Song. Targeting Dendritic Cells with Alpha 1 Antitrypsin has Therapeutic Potentials in Lupus.AAI 2018, Austin, TX. (oral presentation)
124. LiW., S.C. Choi, A Titov, G Abboud, **L Morel**.. Lupus *susceptibility gene Esrrg* regulates Treg development and suppressive function through mitochondrial metabolism. AAI 2018, Austin, TX.
125. Choi, S.C., Abboud, G., Titov, A.A., and **Morel, L.** Autoreactive and immunization-induced follicular helper T cells have opposite glucose and glutamine requirements. AAI 2018, Austin, TX.
126. Brown, J Choi, S.C., Kanda, N., and **Morel, L.** Dietary Tryptophan Modulates Autoimmunity in a Mouse Model of Lupus. AAI 2018, Austin, TX.
127. Abboud G., Seung-Chul Choi, Anton Titov, Wei Li, **Morel, L.**. Protection from lethal Flu infections: lessons from a systemic lupus mouse model.AAI 2018, Austin, TX.
128. Choi S.C., Brown J., Garrett T, and **Morel L**. Microbiota-associated tryptophan catabolism induces autoimmune activation in a mouse model of lupus. Lupus 21st Century 2018 Conference, Sept 13-15, 2018, Armonk, NY.
129. S. John Calise, Georges Abboud, Hideko Kasahara, **Laurence Morel,** and Edward K.L. Chan. Inosine monophosphate dehydrogenase polymerizes in activated T cells. The joint 26th International Conference on Arginine and Pyrimidines & the 1st International Conference on Amino acids and Nucleotides. Shanghai, CN, July 4-7, 2018.
130. Choi SC, Gong M, Brown J,Garrett T, Mohamadzadeh M, **Morel L**. Microbiota-associated tryptophan metabolism induces autoimmune activation in a mouse model of lupus, Metabolites as signalling molecules, Cell Symposium, Poster presentation, December 9-11, 2018.
131. Calise SJ, Abboud G, Kasahara H, Morel L, and Chan EKL. Widespread *in vivo*assembly of IMPDH filaments in proliferating lymphocytes. American Society for Cell Biology and European Molecular Biology Organization Joint Meeting, San Diego, CA; Dec 8-12, 2018.
132. Choi, S.C., Abboud, G., Titov, A.A., and Morel, L. Inhibition of glucose metabolism selectively targets autoreactive follicular helper T cells. Keystone Symposium B cell-T cell interactions, Keystone, CO, Feb. 10-14, 2019.
133. Choi S.C., Gong, M., Brown J., Garrett T, Mohamadzadeh, M. and **Morel L**. Microbial tryptophan metabolism induces autoimmune activation in a mouse model of lupus. Keystone Symposium Microbiome: Chemical Mechanisms and Biological Consequences, Montreal, QE, March 10-14, 2019.
134. Wang, H., Teng, X., Abboud, G., Li, W., Morel, L. TD-Mannose ameliorates systemic lupus erythematosus-like disease in B6.MRL/lpr mouse model. 13th International Lupus Conference. San Francisco, CA, April 5-8, 2019.
135. Huang N, Lai ZW, Choudhary G, Winans T, Kelly R, Banki K, **Morel L**, Perl A. Lupus-Prone SLE1.2.3. Mice Exhibit Loss of Thymus-Derived CD4+CD25+Helios+ Tregs [abstract]. *Arthritis Rheumatol.* 2018; 70 (suppl 10). https://acrabstracts.org/abstract/lupus-prone-sle1-2-3-mice-exhibit-loss-of-thymus-derived-cd4cd25helios-tregs/. Accessed February 18, 2019.
136. Choi, S.C., Cornaby, C., and **Morel, L**. Overexpression of *Pbx1-d*, a novel splice isoformof *Pbx1* associated with lupus susceptibility, regulates regulatory T cell plasticity. AAI 2019, San Diego, CA, May 11-14. Oral Presentation
137. LiW., S.C. Choi, A Titov, G Abboud, **L Morel**.. Lupus susceptibility *gene Esrrg* regulates Treg development and suppressive function through mitochondrial metabolism. AAI 2019, San Diego, CA, May 11-14. Oral Presentation
138. Abboud G., Seung-Chul Choi, Anton Titov, Wei Li, Karl Kai McKinstry, Tara M. Strutt, Shahram Salek-Ardakani, **Morel, L.** Swift protection from Flu infections in a systemic lupus mouse model. AAI 2019, San Diego, CA, May 11-14.
139. Cornaby, C., Zeumer-Spataro, L., Choi, S-C., and **Morel, L.** Lymphocytes populations in murine models of Systemic Lupus Erythematosus exhibit different responses to treatment with metabolic modulators. AAI 2019, San Diego, CA, May 11-14.
140. Brown, J. Choi, S-C., and **Morel, L.** The gut microbiota from lupus-prone B6.*Sle1.Sle2.Sle3* (TC) induces inflammation via a mechanism other than bacterial translocation. AAI 2019, San Diego, CA, May 11-14.
141. Elshikha, A. ; G. Abboud; A. Danos; M. Chen; Y. Yuan; L. Zeumer; **L. Morel;** S. Song. Alpha-1-Antitrypsin Ameliorates Diffuse Alveolar Hemorrhage in the Pristane Induced Lupus Model. . AAI 2019, San Diego, CA, May 11-14.
142. Wyman B, Huang N, Winans T, **Morel L**., Duarte M, Lewis J, Haas M, Perl A. T cell-specific Rab4A activity contributes to pathogenesis of autoantibody production, glomerular disease, and neuropsychiatric symptoms in murine models of systemic lupus erythematosus. ACR/ARP 2019, Atlanta, GA.
143. Huang N, Lai Z, Wyman B, Winans T, Duarte M, Lewis J, Haas M, **Morel L**., Perl A. Rab4A controls mTOR pathway activation, pro-inflammatory lineage development, and disease pathogenesis in lupus-prone mice. ACR/ARP 2019, Atlanta, GA.

Book Chapters:

1. **Morel, L.** and R.K. Vander Meer. Nestmate recognition in *Camponotus floridanus*: Behavioral and chemical evidence for the role of age and social experience. In: Chemistry and biology of social insects, (Eds. J. Eder and H. Rembold), Verlag Peperny, Munich, pp. 471-472, 1987.

2. Vander Meer, R.K., **L. Morel**. Brood pheromones in ants. In: Advances in Myrmecology, (Ed. J.C. Trager), E.J. Brill Publ., New York, pp. 492-513, 1988.

3. Vander Meer, R.K., M.S. Obin and **L. Morel**. Nestmate recognition in monogyne and polygyne populations of the fire ant, *Solenopsis invicta* Buren. In: Social Insects and the Environment, Proc. of the 11th Int'l Cong. IUSSI., (Eds. G.K. Veeresh, B. Mallik and C.A. Viraktamath), Oxford & IBH Publ. Co., New Delhi, India, pp. 280-281, 1990.

4. Vander Meer, R.K., M.S. Obin and **L. Morel**. Nestmate recognition in fire ants: monogyne and polygyne populations. In: Applied Myrmecology: A World Perspective, (Eds. R.K. Vander Meer, K. Jaffe and A.Cedeno) Westview Press, Boulder, CO, pp. 322-328, 1990.

5. Vander Meer, R.K., and **Morel, L**. Nestmate recognition in ants, In: Pheromone communication in social insects (Eds R.K. Vander Meer, M. Breed, M. Winston, and K.E. Espelie), Westview Press, Boulder, CO, pp. 79-1-3, 1998.

1. Mohan, C., **L. Morel**, and E. K. Wakeland. Genetic insights into murine lupus. In: Lupus: Molecular and cellular pathogenesis, (Eds. G.C. Tsokos and G. Krammer) Humana Press, 1999.
2. Rubin Kelly, V., **Morel, L.,** and Foster, M.H. Molecular and genetic basis of lupus nephritis. In: Molecular and Genetic Basis of Renal Disease: A Companion to Brenner and Rector's The Kidney (Eds. D.B. Mount and M.R. Pollak), Elsevier Health Science, Philadelphia, in press.
3. Xu, Y., Zeumer, L.B.,Reeves, W. H. and **Morel, L.** Inducible models of SLE. In: Methods in Molecular Biology – Systemic Lupus Erythematosus. Edited by F. J. Ward and P. Eggleton. Human Press, 2014.
4. **Morel, L**. Chapter 13: Metabolic regulation of lupus. In: Dubois' Lupus Erythematosus and Related Syndromes (9th Edition). Edited by A. La Cava and B. Hahn, Elsevier.

Invited Managing Editor:

1. **Morel, L.** *Role of B cells in systemic and organ-specific autoimmune diseases,* Special Edition of "Encyclopedia of Bioscience", Frontiers of Biosciences (selection and edition of 13 reviews), vol. 12, 2007.
2. **Morel, L.** B cell development and repertoire selection section, in Autoimmune Diseases volume edited by Diamond, B. and Davidson, A., in Encyclopedia of medical Immunology, Ian R. Mackay, Noel Rose [Editors], Springer, 2013.
3. Crispin JC and **Morel L**. Research topic: Mechanisms by which SLE-Associated Genetic Variants Contribute to SLE Pathogenesis. Autoimmunity and Inflammation section, Frontiers in Immunology, 2018.
4. **Morel L**. Special Issue: Immunometabolic disturbances in autoimmune disease. Immunometabolism, 2020.

Peer-reviewed papers:

1. **Morel, L.** Relation entre comportement agressif et privation sociale précoce chez les jeunes immatures de la fourmi *Camponotus vagus* Scop. C. R. Acad. Sci., Paris, ser. D., 296:449-452, 1983.

2. Bonavita-Cougourdan, A. and **L. Morel.** Les activités antennaires au cours des contacts trophallactiques chez la fourmi *Camponotus vagus* Scop. ont-elles valeur de signal? Insectes Soc., 31:113-131, 1984.

3. Bonavita-Cougourdan, A., B. Cougouille-Gauffreteau, G. Le Masne, **L. Morel** and E. Provost. Données récentes sur la variabilité des interactions sociales et des conduites collectives chez des vertébrés et des invertébrés. Psychol. Fr., 29:84-87, 1984.

4. **Morel, L**. Comportement trophallactique de la jeune ouvrière de *Camponotus vagus* Scop.: analyse quantitative de la transmission de substance. C. R. Acad. Sci., Paris, ser. D., 299:245-248, 1984.

5. Bonavita-Cougourdan, A. and **L. More**l. Polyethism in social interactions in ants. Behav. Proc., 11:425-433, 1985.

6. **Morel, L**. Comportement trophallactique de l'ouvrière âgée face à une immature chez la fourmi *Camponotus vagus* Scop. Insectes Soc., 33:32-44, 1986.

7. Bonavita-Cougourdan, A. and **L. Morel**. Relations entre trophallaxie, lésions des antennes et facteurs saisonniers chez la fourmi *Camponotus vagus* Scop. Insectes Soc., 33:132-141, 1986.

8. **Morel, L**. Ontogenesis of the antennal activity associated with food transfer in the callow worker ants. Dev. Psychobiol., 19:413-426, 1986.

9. Blum, M.S., **L. Morel** and H.M. Fales. Chemistry and function of the mandibular gland of *Camponotus vagus* Scop. Comp. Biochem. Physiol., 86B:251-252, 1987.

10. **Morel, L**. and M.S. Blum. Nestmate recognition in *Camponotus floridanus* worker ants: are sisters or nestmates recognized? Anim. Behav., 36:718-725, 1988.

11. Bonavita-Cougourdan, A. and **L. Morel**. Interindividual variability and idiosyncrasy in social behaviours in the ant *Camponotus floridanus* Scop. Ethology, 77:58-66, 1988.

12. **Morel, L.**, R.K. Vander Meer and B.K. Lavine. Ontogeny of the nestmate recognition cues in the red carpenter ant (*Camponotus floridanus*): Behavioral and chemical evidence for the role of age and social experience. Behav. Ecol. Sociobiol., 22:175-183, 1988.

13. **Morel, L**. Role de l'environnement social précoce dans l'ontogenèse de la reconnaissance des membres de la société chez la fourmi *Camponotus floridanus*. Biol. Behav., 13:59-72, 1988.

14. **Morel, L**., and R.K. Vander Meer, C.S. Lofgren. Comparison of nestmate recognition between monogyne and polygyne populations of *Solenopsis invicta* Buren (Hymenopters: Formicidae). Ann. Entomol. Soc. Am., 83:642-647, 1990.

15. Lavine, B.K., R.K. Vander Meer, **L. Morel,** R.W. Gunderson, J.H. Han and A. Stine: False color imaging: An new pattern recognition technique for analyzing chromatographic profile data. J. Microchem., 41:228-295, 1990.

16. Lavine, B.K., **L. More**l, R.K. Vander Meer, R.W. Gunderson, J.H. Han, A.J.I. Ward, A. Bonanno and A. Stine. Pattern recognition studies in chemical communication: Nestmate recognition in *Camponotus floridanus*. Chemometrics Intelligent Lab. Syst., 9:107-114, 1990.

17. **Morel, L**. and R.K. Vander Meer. Do ant brood pheromones exist? Ann. Entomol. Soc. Am., Forum Sect., 81:705-710, 1988.

18. **Morel, L**., R.K. Vander Meer and C.S. Lofgren. Oviposition rate of fire ant queens, *Solenopsis invicta* Buren (Hymenoptera: Formicidae): Comparison of monogyne and polygyne populations. Physiol. Entomol., in press.

19. **Morel, L.**, U.H. Rudofsky, J.A. Longmate, J. Schiffenbauer, and E.K. Wakeland. Polygenic control of susceptibility to murine systemic erythematosus. Immunity, 1:219-229, 1994.

20. **Morel, L**., Yu, Y., Blenman, K.R., Caldwell, R., and Wakeland, E.K. Production of congenic mouse strains carrying NZM/Aeg2410-derived genomic intervals linked to systemic lupus erythematosus expression. Mammalian Genome, 7: 332-335, 1996*.*

22. Vyse, T.J., **Morel, L.**, Tanner,F.J., Wakeland, E.K., Kotzin, B.L. Backcross analysis of genes linked to autoantibody production in New Zealand White mice. J. Immunol., 157: 2719-2727*,* 1996.

23. **Morel, L.**, Mohan, C., Yu, Y., Croker, B.P., Deng, C.H.,Tian, X.H., and Wakeland, E.K. Functional dissection of SLE pathogenesis using congenic mouse strains. J. Immunol., 158: 6019-28, 1997.

\*This article was selected for the 1999 Year Book of Rheumatology, Mosby-Year Book Inc.

24. Mohan, C., **Morel, L.**, Yang, P., and Wakeland, E.K. Genetic dissection of SLE pathogenesis: *Sle2* on murine chromosome 4 leads to B-cell hyperactivity. J. Immunol., *159*: 454-465, 1997.

25. Wakeland, E.K., **Morel, L.**, Achey, K., Yui, M. E., and Longmate, J.A. Speed congenic: A classic technique moves into the fast lane (relatively speaking).Immunology today*, 18*: 473-477, 1997*.*

1. Mohan, C., **Morel, L.**, Yang, P., and Wakeland, E.K. Accumulation of splenic B1a cells with strong antigen presenting capabilities in NZM2410 lupus mice. Arthritis and Rheumatism*, 41:* 1652-1662, 1998.
   1. Mohan, C., Alas, E., **Morel, L.**, Yang, P., and Wakeland, E.K. Genetic dissection of SLE pathogenesis: *Sle1* on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J. Clin. Invest*.,101*: 1362-1372, 1998*.*
2. McNamara, R.K., Stumpo, D.J., **Morel, L.**, Lewis, M.H., Wakeland, E.K., Blackshear, P.J., Lenox, R.H. Effect of reduced myristolated alanine-rich C kinase substrate expression on hyppocampal mossy fiber development and spatial learning in mutant mice: Transgenic rescue and interactions with gen background. Proc. Natl. Acad. Sc. USA, *95*: 14517-14522, 1998.
3. **Morel, L.**, Mohan, C., Yu, Y., Rudofsky, U.H., Schiffenbauer, J., Longmate, J.A. Wakeland, E.K. Complex inheritance of component phenotypes in a murine model of lupus. Mammalian Genome*, 10*: 176-181, 1999*.*
4. Sobel, E.S., Mohan, C., **Morel, L.**, Schiffenbauer, J., and Wakeland, E.K. Genetic dissection of SLE pathogenesis: Adoptive transfer of *Sle1* on murine chromosome 1 by bone marrow. J. Immunol.*, 162:* 2415-22, 1999.
5. Mohan, C., Yu, Y., **Morel, L.**, Yang P., Wakeland, E.K. Genetic dissection of SLE pathogenesis: *Sle3/Sle5* on murine chromosome 7 impact T cell activation, differentiation and cell death. J. Immunol.*, 162:* 6492-6502, 1999*.*
6. **Morel, L.**, Mohan, C., Yang P., Wanatabe, H. Croker, B.P., Gilkeson G., and Wakeland, E.K. Genetic dissection of SLE pathogenesis:A recipe for nephrophilic antoantibodies. J. Clin. Invest., *103:* 1685-1695, 1999*.*
7. **Morel, L.**, Tian, X.-H., Croker, B.P., Wakeland, E.K. Epistatic modifiers of autoimmunity in a murine model of lupus nephritis. Immunity, *11*:131-139, 1999.
8. Wakeland, E.K., Wandstrat, A.E., Liu, K., and **Morel, L.** Genetic dissection of systemic lupus erythematosus. Curr. Opin. Immunol., *11*: 701-707, 1999.
9. Jones, H.C., Lopman, B.A., Jones, T.W., Carter, B.J., Depelteau, J.S., and **Morel, L.** The expression of inherited hydrocephalus in H‑TX rat. Child’s Nerv. Syst. *16*: 578-584, 2000.
10. **Morel, L.**, Croker, B.P, Blenman, K.R., Huang, G., Gilkeson, G., and Wakeland, E.K. Genetic reconstitution of SLE immunopathology with poly-congenic B6.NZM strains. Proc. Natl. Acad. Sc. USA, *97*: 6670-6675, 2000. PMCID: PMC18697.
11. Bahjat, F.R., Dharnidharka, V.R., Fukuzuka, K., **Morel, L.**, Crawford, J.M., Clare-Sazler, M.J., and Moldawer, L.L. Reduced susceptibility of NOD mice to tumor necrosis factorα and D-Galactosamine-mediated hepatocellular apoptosis and lethality. J. Immunol., 165: 6559-6567, 2000.
12. **Morel, L.**, Blenman, K.R., Croker, B.P, Wakeland, E.K. Characterization of a major murine SLE-susceptibility locus, *Sle1,* as a cluster of functionally related loci. Proc. Natl. Acad. Sc. USA, 98: 1787-1788, 2001.
13. Jones, H.C., Depelteau, J.D., Carter, B.J., Lopman, B.A., and **Morel, L.** Genome-wide linkage analysis of inherited hydrocephalus in the H-Tx rat. Mammal. Genome, 12: 22-26, 2001.
14. Jones, H.C., Carter, B.J., Depelteau, J.D., Roman, M., and **Morel, L.** Genetic loci linked to disease severity in the hydrocephalus H-Tx rat. Behavior. Genet., 31: 101-111, 2001.
15. Boackle, S.A., Holers, V.M., Chen, X., Szakonyi, G., Karp, D.R., Wakeland, E.K., and **Morel, L.** *Cr2*, a Candidate Gene in the *Sle1c* Lupus Susceptibility Locus, Encodes a Dysfunctional Protein. Immunity, 15: 775-785, 2001.
16. Terada, N., Hamazaki, T., Oka, M., Hoki, M., Nakano, Y., **Morel, L.**, Petersen, B.E., and Scott, E.W. Spontaneous fusion of bone marrow cells with embryonic stem cells generates pluripotent stem cells. Nature, 416:542-545, 2002.
17. Wu, X., Jiang, N., Deppong, C., Singh, J., Dolecki, G., Moa, D., **Morel, L.**, and Molina, H. A role for the Cr2 gene in modifying autoantibody production in SLE. J.Immunol. 169: 1587-1592, 2002.
18. Sobel, E.S., Satoh, M., Chen, Y., Wakeland, E.K., and **Morel, L.**  The major murine SLE-susceptibility locus Sle1 results in abnormal functions of both B and T cells. J. Immunol., 169: 2694-2700, 2002.
19. Sobel, E.S., **Morel, L.**, Baert, R., Mohan, C., Schiffenbauer, J., and Wakeland, E.K. Genetic dissection of SLE pathogenesis: Evidence for functional expression of *Sle3* in non-T cells. J. Immunol., 169: 4025-32, 2002.
20. Jones, H.C., Carter, B.J., and **Morel, L.** Characteristics of hydrocephalus expression in the LEW/Lms rat strain with inherited disease. Child’s Nervous System, 19: 11-18, 2003.
21. Matsuki, N., Stanic, A.K., Embers,M.E., Van Kaer, L., Leiter, E.H., **Morel, L**., and Joyce S. Genetic dissection of Va14Ja18 natural T cell number and function in autoimmune-prone mice. J. Immunol., 11: 5429-5437, 2003.
22. Erickson, L.D., Lin, L.-L., Duan, B., **Morel, L.**, and Noelle, R.J. A genetic lesion that arrests plasma cell homing to the bone marrow. Proc. Natl. Acad. Sc. USA, 100: 12905-12910, 2003. PMCID: PMC240717
23. Croker, B.P., Gilkeson G., and **Morel, L.** Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus. Genes Immun., 4: 575-585, 2003.
24. Kong,P.L., **Morel, L.**, Croker, B.P. and Craft, J. The centromeric region of chromosome 7 from MRL mice (*Lmb3*) is an epistatic modifier of *Fas* for autoimmune disease expression. J. Immunol. 172: 2785-2794, 2004.
25. Blenman, K. R., Bahjat, F. R., Moldawer, L. L., and **Morel, L**. Aberrant Signaling in the TNFα/TNF Receptor 1 Pathway of the NZM2410 Lupus Prone Mouse. Clin. Immunol., 110: 124-133, 2004.

This paper was the topic of a mini-review in the same issue of Clinical Immunology.

Xie, S. and C. Mohan.Divide and conquer - the power of congenic strains**.** Clin. Immunol., *110*:109-111, 2004.

1. Stohl, W., Xu, D., Metzger, T.E., Kim, K.S., **Morel, L**., and Kotzin, B.L. Dichotomous effects of complete versus partial major histocompatibility complex class II deficiency on circulating autoantibody levels in autoimmune-prone mice. Arthritis and Rheumatism, 50: 2227-2239, 2004.
2. de Souza, C.M., **Morel, L.**. Cabrera, W.H.K, Starobinas, N., Ribeiro,O.G., Siqueira; M., Ibañez,O.M., and De Franco, M. Quantitative trait loci in chromosomes 3, 8 and 9 regulate antibody production against *Salmonella* flagellar antigens in the mouse. Mammalian Genome, 15: 630-636, 2004.
3. Xu, Z., Butfiloski, E.J., Sobel, E.S., and **Morel, L.** Mechanisms of peritoneal B-1a cells accumulation induced by murine lupus susceptibility locus *Sle2.* J. Immunol. 173:6050-6058, 2004.
4. Wandstrat, A.E., Nguyen,C., Limaye, N., Chan, A.Y., Subramanian, A., Tian, X-H., Yim, Y.-S., Pertsemlidis, A. Garner, H.R. Jr., **Morel, L**. and Wakeland,E.K. Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus. Immunity, 21: 769-780, 2004.
5. Wakui M., Kim, J. Butfiloski, E.J., **Morel, L.,** and Sobel, E.S. Impact of a mouse lupus susceptibility locus *Sle3/5* on somatic Ig heavy chain diversification. J. Immunol. 173: 7368-7376, 2004.
6. Chen, Y., Cuda, C., and **Morel, L**. Genetic determination of T cell help in loss of tolerance to nuclear antigens. J. Immunol.,174: 7692-7702, 2005.
7. Stohl, W., Xu, D., Kim, K.S., Koss, M.N., Jorgensen, T., Metzger, T.E., Bixler, S.A., Ambrose, C., Mackay, F., **Morel, L.,** Kotzin, B.L., and Kalled, S.L. BAFF promotes precocious renal disease in mice with incomplete genetic predisposition to systemic lupus erythematosus. Arthritis and Rheumatism, 52: 2080-2091, 2005.
8. Chen, Y., Perry, D., Boackle, S., Sobel, E.S., Molina, H., Croker, B.P., and **Morel, L.** The lupus susceptibility locus *Sle1c* contains several genes producing autoreactive B and T cells. J. Immunol. 175: 1080-1089, 2005.
9. Wakui, M., **Morel, L.**, Butfiloski, E.J., Baert, R. Kim, C., and Sobel, E.S. Genetic dissection of SLE pathogenesis: Partial functional complementation between Sle1 and Sle3/5 demonstrates requirement for intracellular co-expression for full phenotypic expression of lupus. J. Immunol. 175, 1337-1345, 2005.
10. Xu, Z., Duan, B., Croker, B.P., Wakeland, E.K., and **Morel, L**. Genetic dissection of the murine lupus susceptibility locus *Sle2*: contributions to increased peritoneal B-1a cells and lupus nephritis map to different loci. J. Immunol. 175: 936-943, 2005.
11. Litherland, S. A., Grebe, K. M.,Belkin, N. S., Paek,E., Elf, J., Atkinson, M.,**Morel, L**., Clare-Salzler, M. J., and McDuffie M. Nonobese diabetic mouse congenic analysis reveals chromosome 11 locus contributing to diabetes susceptibility, macrophage STAT5 dysfunction, and GM-CSF overproduction. J. Immunol., 175: 4561-4565, 2005.
12. Li, J., Liu, Y., Xie, C., Zhu, J., Kreska, D. **Morel, L**., and Mohan, C. Deficiency of type I interferon may contribute to Sle2-associated component phenotypes. Arthritis and Rheumatism, 52: 3063-3072, 2005.
13. Amital, H., Heilweil, M., Szafer, F., Bar-Tana, R., Ulmansky, R., **Morel,L.,** Foster,M.H., Mostoslavsky, G., Eilat, D., Pizov, G., and Naparstek, Y. Treatment with a laminin-derived peptide suppresses lupus nephritis. J. Immunol., 175: 5516-5523, 2005.
14. Wilson, K.H.S., McIndoe, R.A., Eckenrode, S., **Morel, L.**, Agarwal, A., Croker, B.P., and She, J-X. Alterations of renal phenotype and gene expression profiles due to protein overload in NOD-related mouse strains. BMC Nephrology. 6: 17, 2005.
15. Xu, Z., Duan, B., Croker, B.P., and **Morel, L**. STAT4 deficiency protects mice from lupus nephritis. Clin. Immunol., 120:189-198, 2006. PMID:16713741. DOI:[10.1016/j.clim.2006.03.009](https://doi.org/10.1016/j.clim.2006.03.009)
16. Blenman, K.R.M., Duan, B., Xu, Z., Wan, S., Atkinson, M.A., Flotte, T.R., Croker, B.P., **Morel, L**. IL-10 regulation of lupus in the NZM2410 murine model. Lab. Invest., 86: 1136-1148, 2006.
17. Duan, B.D., Croker, B.P., and **Morel, L.** Lupus resistance associated with expansion of the marginal zone B cell and B-1a cell compartment in an NZM mouse strain. Lab. Invest., 87: 14-28, 2007.
18. Wan, S., Xia, C.Q., and **Morel, L**. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J. Immunol. 178:271-279, 2007. PMID:16924244 DOI:[10.1038/labinvest.3700468](https://doi.org/10.1038/labinvest.3700468)
19. Giles B.M., Kachinski J.J., Tchepeleva, S.N., Croker, B.P., **Morel, L**., and Boackle. S.A. Augmentation of NZB autoimmune phenotypes by the *Sle1c* murine lupus susceptibility interval. J. Immunol., 178: 4667-75, 2007.
20. [Wang, F](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wang%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)., [Roberts, S.M](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Roberts%20SM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)., [Butfiloski, E.J](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Butfiloski%20EJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)., [**Morel, L**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morel%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus)**.**, and [Sobel, E.S](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sobel%20ES%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Acceleration of autoimmunity by organochlorine pesticides: A comparison of splenic B-cell effects of chlordecone and estradiol in (NZBxNZW)F1 mice. [Toxicol Sci.](javascript:AL_get(this,%20'jour',%20'Toxicol%20Sci.');) 99: 141-152, 2007.
21. Rahman, Z., Niu, H., Perry, D., Wakeland, E.K., Manser, T., and **Morel. L.** The autoimmune *Fcgr2b* NZW allele fails to up-regulate its expression in germinal center B cells and leads to increased IgG production. Genes and Immunity, 8: 604-612, 2007. PMID:17713556. DOI:[10.1038/sj.gene.6364423](https://doi.org/10.1038/sj.gene.6364423)
22. Cuda, C., Wan, S., Sobel, E.S., and **Morel, L**. Murine Lupus Susceptibility Locus *Sle1a* controls regulatory T cell number and function in a T cell intrinsic manner. J. Immunol*.* 179: 7439-7447, 2007. PMCID:PMC Journal In Process.
23. Wan, S., Zhou, Z., Duan, B., and **Morel. L.** Dendritic cells from lupus prone mice directly interact with B cells to increase their effector functions. Arthritis and Rheumatism*,* 58: 1741-1750, 2008. PMID:18512810 DOI:[10.1002/art.23515](https://doi.org/10.1002/art.23515)
24. Duan, B., Niu, H. Xu, Z., Sharpe, A.H., Croker, B.P., Sobel, E.S., and **Morel L**. Intrafollicular location of marginal zone B cells is associated with autoimmune pathology in a mouse model of lupus. Lab. Invest., 88: 1008-1019, 2008. PMCID: PMC3731739.
25. Niu, H., Sobel, E.S., and **Morel, L.** Impaired response to T-dependent immunization in lupus-prone mice is B-cell dependent. Eur. J. Immunol., 38: 3028-3040, 2008. PMCID:PMC2828936.
26. Pinedo, P.J., Buergelt, C.D., Donovan, G.A., Melendez, P.G., **Morel, L**., Wu, R., Langaee, T.Y., and Rae, D.O. Candidate gene polymorphisms (BoIFNG, TLR4, SLC11A1) as risk factors for paratuberculosis infection in cattle. Prev. Vet. Med, 91:189-96, 2009.
27. Pinedo, P.J., Buergelt, C.D., Donovan, G.A., Melendez, P.G., **Morel, L**., Wu, R., Langaee, T.Y., and Rae, D.O. Association between CARD15/NOD2 gene polymorphisms and paratuberculosis infection in cattle. Vet. Microbiol. 134: 346-352, 2009.
28. Stohl, W., Jacob, N., Guo, S., and **Morel, L.** Constitutive overexpression of BAFF in autoimmune-resistant hosts drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthr. Rheum., 62: 2432-2442, 2010.
29. Cuda, C.M, Wan, S., Sobel, E.S., Croker, B.P. and **Morel, L**. Murine lupus susceptibility locus Sle1a requires the expression of two sub-loci to induce inflammatory T cells*.* Genes and Immunity, 11: 542-553, 2010. Featured article in the October 2010 issue. PMCID: PMC2958247.
30. Tchepeleva, S.N., Thurman, J.M., Ruff, K., Perkins, S.J., **Morel, L**. and Boackle, S.A. An allelic variant of Crry in the murine *Sle1c* lupus susceptibility interval is not impaired in its ability to regulate complement activation. J. Immunol., 185:2331-9, 2010.
31. Tse, H.M., Thayer, T.C., Steele, C., Cuda C.M., Martello R.D., Ramiya, V., **Morel, L**., Piganelli, J.D. and Mathews C.E.NOD mice deficient in NADPH oxidase activity are defective in adaptive immune effector function and diabetogenesis. J. Immunol., 185: 5247-58, 2010. PMCID: PMC3190397.
32. Xu, Z., Cuda, C.M., Croker, B.P., and **Morel, L**. The NZM2410-derived lupus susceptibility locus *Sle2c1* increases Th17 polarization and induces nephritis in Fas-deficient mice. Arthr. Rheum., 63:764-74, 2011. PMCID: PMC3079951. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079951/
33. Zeumer, L., Sang, A., Niu, H., and **Morel, L**. Murine lupus susceptibility locus *Sle2* activates DNA-reactive B cells through two sub-loci with distinct phenotypes. Genes and Immunity, 12:199-207, 2011. PMCID: PMC3081373.
34. Zhou, Z., Niu, H., Zheng, Y.Y., and **Morel, L.** Autoreactive marginal zone B cells enter the follicles and interact with CD4+ T cells in lupus-prone mice. BMC Immunology, 12:7, 2011. PMCID: PMC3034709.
35. Xu, Z., Vallurupalli, A., Furhman, C., Ostrov, D.A., and **Morel, L.** An NZB-derived locus suppresses chronic graft versus host disease and autoantibody production through myeloid bone-marrow derived cells. J. Immunol., 186:4130-9, 2011. PMCID: PMC3131784
36. Keszei, M., Detre, C., Rietdijk, S., Munoz, P., Romero, X., Castro, W., Berger, S., Calpe, S., Liao, G., Wu, Y., Shin, D.-M., Sancho, J., Zubiaur, M., Morse, H., **Morel, L**., Engel, P., Wang, N., and Terhorst, C. A novel isoform of the Ly108 gene ameliorates lupus. [J Exp Med.](http://www.ncbi.nlm.nih.gov/pubmed/21422172) 208: 811-22, 2011. PMCID: PMC3135348
37. Xu,Z.,Potula, H. H. S.K., Vallurupalli, A., Perry, D., Baker, H., Dozmorov, I., and **Morel, L**. Cell cyclin kinase inhibitor *Cdkn2c* regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus *Sle2c1.* J. Immunol., 186:6673-82, 2011. PMCID:PMC Journal In Process. *Selected for “In this Issue”.*
38. Sobel, E.S., Brusko, T.M., Butfiloski,E.J., Hou, W., Li, S., Cuda, C.M., Abid, A.N., Reeves, W.H., and **Morel, L**. Defective Foxp3 and CD25 induction of by TGFb and retinoic acid in CD4+ T cells from lupus patients. Arthr. Rheum. Ther., 13:R106, 2011. PMCID: PMC3218921.
39. Cuda, C.M., Li, S., Liang, S., Yin, Y., Chen,Y., Potula, H. H. S.K., Xu,Z.,Butfiloski,E., Chang, L.-J., Baker, H., Dozmorov, I., Sobel, E.S., and **Morel, L**. Pre-B cell leukemia homeobox protein is associated with lupus susceptibility in mice and humans. J. Immunol., 188: 604-614, 2012. PMCID:PMC 3253202.
40. Sengupta, M., and **Morel, L.** The role of Pbx1 in T cells. Protein Cell., 2:946-9, 2011. DOI 10.1007/s13238-011-1136-9. PMCID: PMC3724410.
41. Potula, H. H. S.K and **Morel, L**. Genetic variation at an YY-1 response site regulates the expression of cyclin-dependent kinase inhibitor p18*INK4C* transcript in lupus-prone mice. J. Immunol., 188:4992-02, 2012. PMCID:PMC3345103.
42. Iwata, Y., Bostrom, E., Menke, J., Rabacal, W.A., **Morel, L**., and Kelley, V.R. Aberrant macrophages mediate defective repair that triggers lupus nephritis in MRL-*Faslpr* mice. J. Immunol., 188:4568-80, 2012.
43. Perry, D.J., Yin, Y., Telarico, T., Baker, H.V., Dozmorov, I., Wakeland, B., Perl, A., Wakeland, E.K., and **Morel, L**.. Murine lupus susceptibility locus *Sle1c2* mediates CD4+ T cell hyperactivation and maps to estrogen-related receptor gamma *Esrrg.* J. Immunol. 189:793-803, 2012. PMCID: PMC3392454. *Selected for “In this Issue”.*
44. Potula, H.H., Xu, Z. Zeumer, L., Sang, A., Croker, B.P., and Morel, L**.** Cyclin-dependent kinase inhibitor *Cdkn2c* deficiency promotes B1a cell expansion and autoimmunity in a mouse model of lupus. J. Immunol. 189:2931-2940, 2012. PMCID:PMC3436953.
45. Sengupta, M., Liang, S., Potula, H.H.S., Chang, L.J., Morel, L. The SLE-associated Pbx1-d isoform acts as a dominant negative transcriptional regulator. Genes and Immunity, 8: 653-657, 2012, PMCID:PMC3600587.
46. Niu H., Fang G., Tang Y., Xie L., Yang H, **Morel** L., Diamond B., and Zou Y.-R. The function of hematopoietic stem cells is altered by both genetic and inflammatory factors in lupus mice. Blood, 121:1986-1994, 2013. PMID:23315165.
47. Lantow, M., Sivakumar, R., Zeumer, L., Wasserfall, C., Zheng, Y.Y., Atkinson, M.A., and **Morel, L**. The granulocyte colony stimulating factor pathway regulates autoantibody production in a murine induced model of systemic lupus erythematosus. Arthritis Res Ther. 2013; 15(2):R49 Highly Accessed
48. Xu Z., Croker, B.P., and **Morel, L.** The combination of two Sle2 lupus-susceptibility loci and Cdkn2c deficiency leads to T cell-mediated pathology in B6.Faslpr mice. Genes and Immunity. 2013 May 23. doi: 10.1038/gene.2013.28. [Epub ahead of print].
49. Wang, X. , Moghimi, B., Zolotukhin, I., **Morel, L**., Cao, C. and Herzog, R.W.

Immune Tolerance Induction to Factor IX through B Cell Gene Transfer - TLR9 Signaling Delineates between Tolerogenic and Immunogenic B cells. Mol. Therapy, 2014, doi:10.1038/mt.2014.43. [Epub ahead of print].

1. Sang, A., Niu, H., Cullen, J., Choi, S.-C., Zheng, Y.Y., Wang, H., Shlomchik, M.J., and **Morel, L**. Activation of rheumatoid factor-specific B cells is antigen-dependent and occurs outside of germinal centers in the lupus-prone NZM2410 mouse model. J. Immunol., 2014, 193(4):1609-21. PMCID:PMC4119566.
2. Sang, A., Zheng, Y.Y., Li, H., Hsu, H-C., Mountz, J.D., and **Morel, L.** Dysregulated cytokine production by dendritic cells modulates B cell responses in the NZM2410 mouse model of lupus. *PLoS One*, 2014, 9(8):e102151. PMCID:PMC4122346
3. Lu, S., Zeumer, L., Sorensen, H., Riva, A., Croker, B.P., Wallet, S., and **Morel, L.** The murine Pbx1-d lupus susceptibility allele accelerates mesenchymal stem cell differentiation and impairs their immunosuppressive function. J. Immunol., 194(1):43-55. 2015. PMID:25416808 DOI:[10.4049/jimmunol.1401851](https://doi.org/10.4049/jimmunol.1401851). *Selected for “In this Issue”.*
4. Yin, Y. Choi, S.C., Xu, Z., Perry, D.J., Seay, H., Croker, B.P., Sobel, E.S., Brusko, T.M., and **Morel, L**. Normalization of CD4+ T cell metabolism reverses lupus. Science Translational Med., 7, 274ra18 (2015). PMCID:[PMC5292723](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292723/). Related “Focus”: M. M. Mehta, N. S. Chandel, Targeting metabolism or lupus therapy. Sci. Transl. Med. 7, 274fs5 (2015).
5. Rogers, G.L., Suzuki, M., Zolotukhin, I., Markusic, D.M., **Morel, L**., Lee, B., Ertl, H.C.J., and Herzog, R.W. Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer. J. Innate Immun., DOI: 10.1159/000369273, 2015*.* PMCID:[PMC4417066](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417066/).
6. Xu Z., and **Morel, L.** Contribution of B-1a cells to systemic lupus erythematosus in the NZM2410 mouse model. Ann. NY Acad. Sci., 2015, doi: 10.1111/nyas.12607.
7. Tusi, B.K., Salz, T., Deng, C., Zeumer, L., Li, Y., So, E.C.W., Morel, L., Qiu, Y, and Huang, S. Setd1a regulates pro-B cell to pre-B cell development through H3K4 trimethylation and IgH rearrangement. FASEB J., 2014, Dec 30. pii: fj.14-263061. [Epub ahead of print]
8. Doerfler, P., Nayak, S., Herzog, R.W., **Morel, L.,** and Byrne, B.J. BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease. Clin. Immunol. 2015 Apr 1;158(2):140-147. doi: 10.1016/j.clim.2015.03.022. [Epub ahead of print]
9. Sang, A., Zheng, Y.Y., Choi, S.-C., Wang, H., Shlomchik, M.J., and **Morel, L**. Genetic and cellular dissection of the activation of AM14 rheumatoid factor B cells in a mouse model of lupus. J Leukoc Biol. 2015 Aug;98(2):209-21. PMCID:PMC4501674.
10. Li, H., Fu, Y.-X., Zhou, Y., Crossman, D.K., Wu, Q., Yang, P.A., Li, J., Luo, B., **Morel, L.,** Kabarowski, J.H., Yagita, H., Ware, C., Hsu, H-C., and Mountz, J.D. Type I interferons promote lupus through disruption of the lymphotoxin receptor-mediated mechanosensing MKL1 pathway in spleen marginal zone macrophages.J. Clin. Invest., 2015 Jul 1;125(7):2877-90. doi: 10.1172/JCI81059. Epub 2015 Jun 22. PMID:26098211. PMCID:[PMC4563689](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563689/).
11. Erin Garrigan,MS,MD1,2,3 , Nicole S. Belkin, MD1,2,3,Federica Seydel1,2,3 , Zhao Han, MS1 Jamal Carter,MD1,3, Marcia McDuffie, MD4, Laurence Morel, PhD1, Ammon B. Peck, PhD1, Michael Clare-Salzler, MD1, Mark Atkinson, PhD1, Clive Wasserfall, MS1, Abdoreza Davoodi-Semiromi, PhD1,3, Jingda Shi, PhD/MD3,5, Carrie-Haskell-Luevano, PhD3,6, Li-Jung Yang,MD1, John Alexander1,3, Ramona Bober3,7, Autumn Cdebaca3,7,Teresa Piliant7, Corin Riggs7,8, Matthew Amick1,8, and Sally A. Litherland. Csf2 & Ptgs2 Epigenetic Dysregulation in Diabetes Prone Bi-Congenic B6.NODC11bxC1tb Mice. Genetics and Epigenetics. 2015 Oct 11;7:5-17. doi: 10.4137/GEG.S29696
12. Yin, Y. Choi, S.C., Xu, Z., and **Morel, L**. Mitochondrial metabolism and not glycolysis fuels effector CD4 T cells in lupus. J Immunol. 2016 Jan 1;196(1):80-90. doi: 10.4049/jimmunol.1501537. Epub 2015 Nov 25. PMCID: PMC468499.
13. [Li W](https://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20W%5BAuthor%5D&cauthor=true&cauthor_uid=26911849), [Li H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20H%5BAuthor%5D&cauthor=true&cauthor_uid=26911849), [Zhang M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhang%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26911849), [Wang M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26911849), [Zhong Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhong%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=26911849), [Wu H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wu%20H%5BAuthor%5D&cauthor=true&cauthor_uid=26911849), [Yang Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Yang%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=26911849), [**Morel L**](https://www.ncbi.nlm.nih.gov/pubmed/?term=Morel%20L%5BAuthor%5D&cauthor=true&cauthor_uid=26911849)**,** [Wei Q](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wei%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=26911849). Quercitrin ameliorates the development of systemic lupus erythematosus-like disease in a chronic graft-versus-host murine model. Am J Physiol - Renal Physiol,2016, 311(1):F217-26. doi: 10.1152/ajprenal.00249.2015. PMID: 26911849.
14. Holodick, N.E., Zeumer, L., Rothstein, T.L, **Morel, L**. Expansion of B-1a cells with germline heavy chain sequence in lupus mice. Frontiers in Immunol. 2016 Mar 24;7:108. doi: 10.3389/fimmu.2016.00108.
15. Choi, S.C., Hutchinson, T.E., Titov. A.A., Seay, H. Li, S. Brusko, T. J., Salek-Ardakani, S., **Morel, L**. The lupus susceptibility gene Pbx1 regulates the balance between follicular helper T cell and regulatory T cell differentiation. J. Immunol., 2016 197(2):458-69. doi: 10.4049/jimmunol.1502283. PMCID:[PMC4935607](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935607/)
16. Elshikha, A.S., Lu, A., Chen, M.-J., Akbar, M., Zeumer, L., Ritter, A., Elghamry, H., Mahdi, M. A., **Morel, L.,** and Song, S. Alpha 1 antitrypsin inhibits dendritic cell activation and attenuates nephritis in a mouse model of lupus. PLoSOne, 2016 May 27;11(5):e0156583. doi: 10.1371/journal.pone.0156583. eCollection 2016
17. Khass, M., Schelonka, R.L., Liu, C.R., Elgavish, A., **Morel, L**., Burrows, P.D., Schroeder, H.W. Jr. C57BL/6 mice congenic for the lupus susceptibility loci sle1, sle2, or sle3 and the ΔD-iD arginine enriched DH gene segment demonstrate alterations in B cell development and enhanced production of dsDNA binding IgM. Autoimmunity, **2017** Feb;50(1):42-51. doi: 10.1080/08916934.2016.1272597.
18. Dwivedi, N., Hedberg, A., Zheng, Y.Y., Neeli, I., Satoh, M., **Morel, L**., Rekvig, O.P., and Radic, M.Immunological Tolerance to Deiminated Histones in BALB/c and Autoimmune-Prone Mouse Strains. Frontiers in Immunology, 8:362. **2017**.doi: 10.3389/fimmu.**2017**.00362. eCollection
19. Niu, Y., Sengupta, M., Choi, S.C., Titov, A.A., **Morel, L**. The Pbx1 lupus susceptibility gene regulates CD44 expression. Mol. Immunol., 2017 85:148-154. DOI:[10.1016/j.molimm.**2017**.02.016](https://doi.org/10.1016/j.molimm.2017.02.016). PMID:28257976 PMCID:[PMC5389453](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389453/).
20. Xu, Z., Xu, J., Ju, J., and **Morel, L.** A Skint6 Allele Potentially Contributes to Mouse Lupus. . **2017** May 11. doi: 10.1038/gene.**2017**.8. [Epub ahead of print].
21. Cooper, M., Perrin, G.Q., Biswas, M., Martino, A.T, **Morel, L**., Terhorst, C., Hoffman, B.E. Herzog, R. Regulatory T cells and TLR9 Activation Shape Antibody Formation to a Secreted Transgene Product in AAV Muscle Gene Transfer. Cell. Immunol., http://dx.doi.org/10.1016/j.cellimm.2017.07.012.
22. Choi SC, Xu Z, Li W, Yang H, Roopenian D, Morse HC III and **Morel L.** Relative contributions of B cells and dendritic cells from lupus-prone mice to CD4+ T cell polarization. J. Immunol., 2018 200(9):3087-3099. doi: 10.4049/jimmunol.1701179. PMID:29563177 PMCID:[PMC5915918](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563689/).
23. Caron N, Genin EC, Marlier Q, Verteneuil S, Beukelaers P, **Morel** L, Hu MG, Hinds PW, Nguyen L, Vandenbosch R, Malgrange B. [Proliferation of hippocampal progenitors relies on p27-dependent regulation of Cdk6 kinase activity.](https://www.ncbi.nlm.nih.gov/pubmed/29728713) Cell Mol Life Sci. 2018 May 4. doi: 10.1007/s00018-018-2832-x. [Epub ahead of print]. PMID:29728713
24. Sivakumar R., Abboud G., Mathews C.E., Atkinson M.A., **Morel L.** Protective role of myeloid cells expressing a G-CSF receptor polymorphism in an induced model of lupus. Frontiers in Immunology. 2018 May 9;9:1053. doi: 10.3389/fimmu.2018.01053.
25. Choi SC, Titov A., Abboud, G., Seay H, Brusko T.J. Roopenian D., Salek-Ardakani S. and **Morel L**. Inhibition of glucose metabolism selectively targets autoreactive follicular helper T cells. [Nat Commun.](https://www.ncbi.nlm.nih.gov/pubmed/30348969) 2018 Oct 22;9(1):4369. doi: 10.1038/s41467-018-06686-0. PMID:30348969; PMCID:[PMC6197193](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197193/).
26. Abboud G., Choi SC, Kanda N., Zeumer-Spataro L. Roopenian, D.C., and Morel L. Inhibition of glycolysis reduces disease severity in an autoimmune model of rheumatoid arthritis. Frontiers in Immunology. 2018 Sep 3;9:1973. doi: 10.3389/fimmu.2018.01973. eCollection 2018.
27. Hukkapalli, S; Ambadapadi, S. Varkoly, K.; Jiron, J.; Aguirre, I.; Bhattacharyya, I.; **Morel, L**.; Lucas, A.; Kesavalu, L. Impaired innate immune signaling due to combined Toll-like receptor 2 and 4 deficiency affects both periodontitis and atherosclerosis in response to polybacterial infection. Path. Diseases.  2018 Nov 1;76(8). doi: 10.1093/femspd/fty076.
28. Elshikha, A.S., Yuan, Y., Lu, Y., Chen, M.-J., Abboud, G., Akbar, M., Plate, H., Wolney, H., Hoffman, T, Tagari, E., **Morel, L.,** and Song, S. Alpha 1 antitrypsin gene therapy extends the life-span of lupus-prone mice. Molecular Therapy - Methods & Clinical Development, 2018 Oct 18;11:131-142. doi: 10.1016/j.omtm.2018.10.007.
29. Calise SJ, Abboud G, Kasahara H, **Morel L**, Chan EKL. Immune response-dependent assembly of IMP dehydrogenase filaments. Frontiers in Immunology. 2018 Nov 29;9:2789. doi: 10.3389/fimmu.2018.02789. eCollection 2018
30. Li, W., Qu, G. Choi, S.C., Cornaby, C., Titov, A., Kanda, N., Teng, X., Wang, H., and Laurence Morel. Targeting T cell activation and lupus autoimmune phenotypes by inhibiting glucose transporters Frontiers in Immunology. 2019 Apr 17;10:833. doi: 10.3389/fimmu.2019.00833. eCollection 2019.
31. Ju, J., Xu, J., Zhu, Y., Fu, X., **Morel L.,** Xu. Z. A variant of the histone-binding protein sNASP contributes to mouse lupus. Frontiers in Immunology, 2019, 10: 637, doi: 10.3389/fimmu.2019.00637.
32. Titov AA, Brusko TM, Sobel, E.S. **Morel L**.Metformin inhibits the type 1 interferon response in human CD4+ T cells. J. Immunol. 2019 Jun 3. pii: ji1801651. doi: 10.4049/jimmunol.1801651. [Epub ahead of print].
33. Yong Ge, Minghao Gong, Mojgan Zadeh, Jing Li, Jeffrey R. Abbott, Wei Li, Laurence **Morel**, Roberto Sonon, Nitin T. Supekar, Parastoo Azadi, Yating Wang, Dean P. Jones, Shuzhao Li and Mansour Mohamadzadeh. Regulating colonic dendritic cells by commensal glycosylated large surface layer protein A to sustain gut homeostasis against pathogenic inflammation. Mucosal Immunol., doi.org/10.1038/s41385-019-0210-0.
34. Shirley JL, Keeler GD, Sherman A, Zolotukhin I, Markusic DM, Hoffman BE, **Morel LM**, Wallet MA, Terhorst C, Herzog. RW. Type I Interferon Sensing by Conventional Dendritic Cells and CD4+ T Help are both Requisite for Cross-priming of AAV Capsid-specific CD8+ T Cells. Mol Ther. 2019 Nov 15. pii: S1525-0016(19)30507-6. doi: 10.1016/j.ymthe.2019.11.011. [Epub ahead of print] PMID:31780366.
35. Choi SC, Brown J, Gong MH, Michailidis G, Garrett T, Mohamadzadeh M, **Morel L.** Microbiota-associated tryptophan catabolism induces autoimmune activation in a mouse model of lupus. Sci. Trans. Med., in revision.
36. Fu C, LuY, WilliamsMA, BrantlyML, VentetuoloCE, **MorelL**, MehradB, ScottEW, BryantAJ.Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodeling. British J Pharmacol., 2019 Dec 3. doi: 10.1111/bph.14945. [Epub ahead of print] PMID:31793661
37. Ahmed S. Elshikha1,3, Georges Abboud2, Lonneke Erikelens1, Yuanqing Lu1, Mong-Jen Chen1, Ye Yuan1, Godelieva Ponjee1, Leilani Zeumer2, Minoru Satoh4, Laurence Morel2 and Sihong Song1. Alpha-1-Antitrypsin Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice. J. Clin. Med. ug 29;8(9). pii: E1341. doi: 10.3390/jcm8091341. PMID:31470606
38. Sun,F.,Wang, H., Liu, Z.; Geng, S.; Wang, H.; Wang, X.; Li, T., Shuang Ye, S., Morel, L., Teng, X., Wan, W., and Lu, L. Metformin in systemic lupus erythematosus, The Lancet, 2020. Accepted 1/6/20.
39. Titov AA, Perry DJ, Schultz AR, Brusko TM, **Morel L**.. Immunophenotyping reveals two distinct SLE subgroups based on T cell activation level in an ethnically mixed cohort. Arthritis Rheum. *In preparation.*

Invited reviews

1. Wakeland, E.K., **Morel, L.**, Mohan, C., and Yui, M. Genetic dissection of lupus nephritis in murine models of SLE. J. Clin. Immunol., *17:* 272-281, 1997.
2. **Morel, L.** and Wakeland, E.K. Susceptibility to lupus nephritis in the NZB/NZW model system. Current Opinion in Immunology, *10*: 718-723, 1998.
3. **Morel, L.**, Yui, M., and Wakeland, E.K. La contribution des modeles murins a la comprehension des maladies autoimmunitaires. In: Les modeles animaux de maladies humaines genetiquement determinees, Annales de l’Institut Pasteur - Actualites, *9:* 351-360*,* 1998*.*
4. Morel, L., and E. K. Wakeland. Lessons from the NZM and B6.NZM congenic strains. In: Genetics of SLE (Ed. T. Shirai). Int. Rev. Immunol., 19: 423-446, 2000.
5. Morahan, G., and Morel, L. Genetics of autoimmunity in patients and models. Current Opinions in Immunol., 14: 803-811, 2002.
6. **Morel, L.** Mouse models of human autoimmune diseases: Essential tools that require the proper controls. PloS Biol., 2:E241, 2004.
7. Chen, Y., and **Morel, L**. Genetics of T cell defects in lupus. Cell. Mol. Immunol. 2:403-409, 2005.
8. **Morel, L.** PI3K controls B cells’ sweet tooth for growth. Inside Blood invited capsule, Blood, 107: 4201 – 4202, 2006.
9. Xu, Z., Duan, B. and **Morel, L.** Genetics of autoreactive B cells. In: *Role of B cells in systemic and organ-specific autoimmune diseases,* L. Morel Ed. Frontiers in Biosciences, 12: 1707-1721, 2007.
10. Duan, B, and **Morel, L**. Role of B-1a cells in autoimmunity. Autoimm. Rev., 5, 403-408, 2006.
11. **Morel, L.** Genetics of human of lupus nephritis. Seminars in Nephrology, 27, 2-11, 2007.
12. **Morel, L.** Genetics of SLE: Evidence from mouse models. Nat. Rev. Rheumatol., 6, 348-357, 2010. http://www.ncbi.nlm.nih.gov/pubmed/20440287
13. Xu, Z. and **Morel, L.** Genetics of systemic lupus erythematosus: Contributions of mouse models in the era of human genome-wide association studies. Discov. Med., 10, 71-78, 2010.
14. Perry, D., Sang, A., Yin, Y., Zheng Y.Y., and **Morel, L**. Murine models of systemic lupus erythematosus. J. Biomed. Biotech., 2011:271694, 2011. PMCID: PMC3042628.
15. Perry, D, Peck, A.B., Carcamo, W.C, **Morel, L.,** and Nguyen, C.Q. The new frontiers of TH17 cells in systemic lupus erythematosus. Arthritis, 2011;2011:810649. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3226200/?tool=pubmed
16. **Morel, L.** Editorial: AICDA catalytic domain as a target to eliminate pathogenic autoantibodies. Arthritis and Rheumatism, 2011 Jan 21. doi: 10.1002/art.30256. PMCID:PMC Journal In Process.
17. **Morel, L.** Mapping Lupus Susceptibility Genes in the NZM2410 mouse model. Adv. Immunol., 115:113-39, **2012**; PMID:22608257, PMCID:PMC Journal In Process
18. Sang, A., Yin, Y., Zheng Y.Y., and **Morel, L**. Animal models of molecular pathology: systemic lupus erythematosus. [Prog Mol Biol Transl Sci](http://www.ncbi.nlm.nih.gov/pubmed/22137436), 105: 321-370, 2012.PMCID: PMC3190397.
19. Sang, A., Zheng Y.Y., and **Morel, L**. Contributions of B cells to lupus pathogenesis Molecular Immunology, 2013 Dec 11. pii: S0161-5890(13)00564-6. doi: 10.1016/j.molimm.2013.11.013. [Epub ahead of print]
20. Xu, Y., Zeumer, L., **Reeves,** W.H., **Morel,** L. [Induced murine models of systemic lupus erythematosus.](http://www.ncbi.nlm.nih.gov/pubmed/24497358) Methods Mol Biol. 2014;1134:103-30. PMCID:PMC Journal In Process
21. Sivakumar, R., Atkinson, M., Mathews, C.E. and **Morel, L.** G-CSF: A friend or foe?Immunome research, 2015 11:S2. http://dx.doi.org/10.4172/1745-7580.S2.007
22. Doerfler, P., Nayak, S., Corti, M., **Morel, L.,** Herzog, R.W., and Byrne, B.J. Targeted Approaches to Induce Immune Tolerance for Pompe Disease Therapy. Molecular Therapy Methods and Clinical Development. 2016, Jan 27;3:15053. doi: 10.1038/mtm.2015.53.
23. Li, W., Sivakumar, R., Titov. A.A., Choi, S.-C., and **Morel, L**. Metabolic factors that contribute to lupus pathogenesis. Crit. Rev. Immunol., 2016, 36:75-98. DOI: [10.1615/CritRevImmunol.2016017164](https://doi.org/10.1615/CritRevImmunol.2016017164). PMID:27480903.PMCID:PMC5278665.
24. Choi, S.C., Titov. A.A., Sivakumar, R., Li, W., and **Morel, L**. Immune metabolism in systemic lupus erythematosus. Curr. Rheum. Rep., 2016, 18: 66. DOI: 10.1007/s11926-016-0615-7. PMID:27709413.
25. Choi, S.C., and **Morel, L**. B cell contribution of the CD4+ T cell inflammatory phenotypes in lupus. Autoimmunity, 2017; 50(1): 37–41. DOI: 10.1080/08916934.2017.1280028.
26. Morel, L. Immunometabolism in SLE. Nat. Rev. Rheumatol. May;13(5):280-290. doi: 10.1038/nrrheum.**2017**.43. Epub **2017** Mar 31.
27. Li, W., Titov. A. A., and **Morel, L**. Mouse models of systemic lupus erythematosus. Curr. Opin. Rheumatol. **2017** Sep;29(5):434-441. doi: 10.1097/BOR.0000000000000412. PMID:28537986. PMCID:[PMC5815391](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815391/).
28. Teng, X., Li, W., Cornaby, C., **Morel, L**. Immune cell metabolism in autoimmunity. Clin. Exp. Immunol., First published: 15 February 2019. doi: 10.1111/cei.13277.
29. Teng, X., Cornaby, C., Li, W., **Morel, L**. 2019. Metabolic regulation of pathogenic autoimmunity. Therapeutic targeting**.** Cur. Opin. Immunol. 61:10-16. doi: 10.1016/j.coi.2019.07.001. PMID: 31422315.
30. Crispin JC and **Morel L**. Editorial: Mechanisms by which SLE-Associated Genetic Variants Contribute to SLE Pathogenesis. Autoimmunity and Inflammation section, Frontiers in Immunology, 2019,10:2808. doi: 10.3389/fimmu.2019.02808. eCollection 2019. PMID:31849982; PMCID:[PMC6901671](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901671/)
31. Choi, S.C., **Morel, L**. Immune metabolism regulation of the germinal center response. Exp. Mol. Med., 2020In Press
32. Immune metabolism regulation of lupus. Immunological Rev. 2020

**Webinar**

Inhibition of glucose metabolism selectively targets autoreactive follicular helper T cellsNanostring webinar, Aug 28, 2019

[https://www.nanostring.com/company/events-archive/inhibition-glucose-metabolism-selectively-targets-autoreactive-follicular-helper-t-cells](https://urldefense.proofpoint.com/v2/url?u=https-3A__www.nanostring.com_company_events-2Darchive_inhibition-2Dglucose-2Dmetabolism-2Dselectively-2Dtargets-2Dautoreactive-2Dfollicular-2Dhelper-2Dt-2Dcells&d=DwMGaQ&c=sJ6xIWYx-zLMB3EPkvcnVg&r=jrEEuLD85kK3GFBIAN6CZ0pxS2c4_ztW-I6lKpxLqxA&m=HZnrkvHfpKf80RNpDxkrWtr-E9HiE211VFrj-84sdNE&s=kkBMMPfwqsCOr9LSsFO0JOwFRejT41O735x9xxIxB00&e=)

**Patents**

Wakeland, E.K., Wandstradt, a., and Morel, L. Isolation of genes within *Sle1b* that mediate a break in immune tolerance. UTSD: 722, May 17, 2000.

Morel, L. and Yin, Y. TREATMENT OF LUPUS USING METABOLIC MODULATORS, U.S. Provisional Application No.: 62/107,160, January 23, 2015

**TEACHING EXPERIENCE**

* GMS 6140: 2-4 lectures and 1 TBL lab, Spring 2013-present
* GMS6921 Immunology advanced concentration Journal club: Spring 2001-present. Course Director.
* GMS 6337: [B Cell Development in Health and Disease](file:///W:\www.med.ufl.edu\IDP\courses\Syllabus\GMS6905-BCellDevel-Sp2007.doc) 2007-present Course Director.
* GMS 5905: Special Topics:  Immunology & Microbiology Grant Writing
  + 2009. Course Director.
  + 2016. Co-director
* Medical Student Basic Immunology Module (W. Winter course Director), Discussion leader, 1992-2011.
* GMS 6030: Autoimmunity
  + 1999 3 lectures
  + 2001 course director
  + 2002 course director
  + 2003 1 lecture
  + 2006: course director
  + 2007: 1 lecture
* GMS 6001: Core Genetics
  + 1999 2 lectures
  + 2000 6 lectures
  + 2001 2 lectures
* GMS 6011: Mouse Genetics
  + 2001 7 lectures
  + Spring 2002 course director
  + Fall 2002-2007: course director
* GMS6381 [Cellular & Molecular Basis of Kidney Diseases](http://idp.med.ufl.edu/courses/Syllabus/GMS6381-SpTopPathKidneySp06.html):
  + 2004 2 lectures
  + 2006 2 lectures
  + 2008 2 lectures
* ICBR Tools for recombinants DNA workshop March 6-10, 2000: one lecture:
* Genetic analysis of disease susceptibility
* Pathology Residents Molecular Pathology rotation “wet lab” 2000 4 lectures
* Pathology Residents Molecular Pathology 2003 1 lecture
* Direction of undergraduate research projects, Department of Microbiology and Cellular Biology, 1992-date.

Graduate Education leadership:

# Member of the IDP Graduate student admission committee 2000 - 2001.

* Co-director of the IDP Immunology Advanced Concentration, 2002 – 2009.
* Member of the IDP Graduate Program Advisory Board, 2000 – 2009.
* T32 Training Grant “Immunologic/Genetic Mechanisms of Rheumatic Disease” (W.H. Reeves PI), co-I, Advisory Committee member, 2005-present.

Mentorship:

* Kim Blenman, Masters student, 2000-2001.
* Anusha Vallurupalli, M.D., Masters student, 2009-2010.
* Kim Blenman, Graduate student, 2001-2004.
* Biyan Duan, Graduate student, 2002-2006.
* Carla Cuda, Graduate student, 2004-2008.
* Daniel Perry, Graduate student, 2006-2011.
* Allison Sang, Graduate student, 2009-2013.
* Yiming Yin, Graduate student, 2010-2014.
* Ying Li Zheng, Graduate student, 2010-2014.
* Ramya Sivakumar, Graduate student, 2012-2016.
* Wei Li, Pekin University PhD student, 2014-2016.
* Anton Titov, Graduate student, 2015-2019.
* Josephine Brown, Graduate student: 2017-present.
* Tracoya Roach, Graduate student: 2017-present.
* YiFang Chan, M.D. Postdoctoral Fellow, 2002-2004.
* Zhiwei Xu, Ph.D. Postdoctoral Fellow, 2002-2009.
* Haitao Niu, Ph.D. Postdoctoral Fellow, 2005-2009.
* Suigui Wan, M.D. Postdoctoral Fellow, 2005-2007.
* Biyan Duan, M.D., Ph.D. Postdoctoral Fellow, 2006-2007.
* Zhenhai Zhou, M.D., Ph.D. Postdoctoral Fellow, 2007- 2009.
* Carla Cuda, Ph.D. Postdoctoral Fellow, 2009.
* Hari Hara Potula, Ph.D. Postdoctoral Fellow, 2009-2013.
* Shujuan Liang, M.D., Postdoctoral fellow, 2010-2011
* Margareta Lantow, Ph.D. Postdoctoral fellow, 2011-2012
* Mayami Sengupta, Ph.D., Postdoctoral fellow, 2011-2013
* Seung-Chul Choi, Ph.D., Postdoctoral fellow, 2013- December 2017.
* Yiming Yin, PhD, Postdoctoral fellow, May 2014-March 2015.
* Georges Abboud, PhD, Postdoctoral fellow, January 2017 – December 2017.
* Wei Li, PhD. Postdoctoral fellow, March 2017 – present.
* Caleb Cornaby, PhD. Postdoctoral fellow, March 2018 – June 2019.
* Haiting Wang, PhD, visiting Postdoctoral fellow from Shanghai JiaoTong University School of Medicine, March 2018 – August 2019.
* Sophie Zang, Postdoctoral fellow, October 2018 – present
* Ahmed Elshika, Postdoctoral fellow, September 2019 – present
* Minghao Gong, Postdoctoral fellow, October 2019 – present
* Zhiwei Xu, Ph.D. Research Assistant Professor, KO1 award recipient 2009-2014.
* Kristiana Fredenburg, M.D., Ph.D., Assistant Professor, UF CTSI KL2 Scholar Multidisciplinary Program recipient, 2017-2019.
* Seung-Chul Choi, Ph.D., Research Assistant Scientist, 2018-
* Georges Abboud, Ph.D., Research Assistant Scientist, 2018-
* Xiang Yu (Shirley) Teng, MD, Associate Professor, Visiting scientist from Shanghai JiaoTong University School of Medicine, November 2017 – November 2019.
* Andrew Bryant, MD, Assistant Professor in the Pulmonary Division (mentoring with immunological aspects of his research)

Graduate students’ committee membership

1. Stormy Chamberlain, College of Medicine Inter Disciplinary Graduate Program, 1999- 2003.
2. Xuezhong Cai, Department of Pathobiology, College of Veterinary Medicine, 2000-2002.
3. Frances Bajhat, College of Medicine Inter Disciplinary Graduate Program, 2000-2002.
4. Christin Collins, College of Medicine Inter Disciplinary Graduate Program, 2001-2005.
5. J.G. Gao, College of Medicine Inter Disciplinary Graduate Program, 2001-2004.
6. Liya Pi, College of Medicine Inter Disciplinary Graduate Program, 2002-2005.
7. QuigGuo Rua, College of Medicine Inter Disciplinary Graduate Program, 2002-2004.
8. Rahul Kanadia, College of Medicine Inter Disciplinary Graduate Program, 2002-2004.
9. Chris Mueller, College of Medicine Inter Disciplinary Graduate Program, 2002-2006.
10. Chris Mariani, College of Medicine Inter Disciplinary Graduate Program, 2002-2006.
11. Bei Wang, College of Medicine Inter Disciplinary Graduate Program, 2004-2007.
12. Kindra Kelly, College of Medicine Inter Disciplinary Graduate Program, 2004-2007.
13. Ashley Martino, College of Medicine Inter Disciplinary Graduate Program, 2004-2008.
14. Tolga Barker, College of Medicine Inter Disciplinary Graduate Program, 2004-2007.
15. Donghang Zheng, College of Medicine Inter Disciplinary Graduate Program, 2004-2006
16. Matt Parker, College of Medicine Inter Disciplinary Graduate Program, 2005-2008.
17. Pablo Pinedo, Department of Infectious Diseases, College of Veterinary Medicine, 2006- 2008
18. Josh Powe, DVM, Department of Pathobiology, College of Veterinary Medicine, 2006-2009.
19. Sushrusha Nayak, College of Medicine Inter Disciplinary Graduate Program, 2007-2010.
20. Erika Eksioglu, College of Medicine Inter Disciplinary Graduate Program, 2007-2010.
21. Isaac Boss, College of Medicine Inter Disciplinary Graduate Program, 2007-2011.
22. Yaima Luzardo, College of Medicine Inter Disciplinary Graduate Program, 2008-2012.
23. Christopher Furhman, College of Medicine Inter Disciplinary Graduate Program, 2009-2014.
24. Shindu Arivazhagan, College of Medicine Inter Disciplinary Graduate Program, 2009-2014.
25. Yuan Xu, College of Medicine Inter Disciplinary Graduate Program, 2009-2014.
26. Judit Cserny, College of Medicine Inter Disciplinary Graduate Program 2011-2017.
27. Christina Graves, College of Medicine Inter Disciplinary Graduate Program 2012-2016
28. Robert Whitener, College of Medicine Inter Disciplinary Graduate Program 2013-2016
29. Pritesh Desai, College of Medicine Inter Disciplinary Graduate Program 2013-2017.
30. Britney Newby, UF MD-PhD program, 2014-2017.
31. McEnzie Williams, College of Medicine Inter Disciplinary Graduate Program 2015-
32. Olivia Bailey, College of Medicine Inter Disciplinary Graduate Program 2015-
33. Jamie Shirley, College of Medicine Inter Disciplinary Graduate Program 2015-2019
34. Melanie Shapiro, College of Medicine Inter Disciplinary Graduate Program 2016-
35. Ashley Zuniga, College of Medicine Inter Disciplinary Graduate Program 2016-
36. Minghao Gong, Department of Infectious Diseases, College of Veterinary Medicine 2016-2019
37. Niousha Ahmari, College of Medicine Inter Disciplinary Graduate Program 2017-2018
38. Sabrina Freeman, Biomedical Engineering PhD program, 2017-
39. Jessica Stanfield, Masters student, 2016-2017.
40. Ahmed Elshikha, College of Pharmacy PhD program, 2016-2019
41. Gavin Golas, College of Medicine Inter Disciplinary Graduate Program 2017-2019.
42. Jatin Sharma, Department of Microbiology and Cell Science, 2018-
43. Shanan Emmanuel, College of Medicine Inter Disciplinary Graduate Program 2019-
44. Mesfin Gobena,College of Medicine Inter Disciplinary Graduate Program 2019-
45. Leeana Peters, College of Medicine Inter Disciplinary Graduate Program 2019-
46. Addelynn Sagadevan, Genetic Institute Graduate Program 2019-

PhD thesis external examiner:

* Justin Boucher, Department of Microbiology and Immunology, University of Miami, Miami FL, July 19, 2016
* Elizabeth Adkins, Tufts University and the Jackson Laboratory, Bar Harbor, ME, August 5, 2016.
* Yuriy Baglaenko, Krembil Research Institute, University Health Network, Toronto, CA, October 7, 2016.

Undergraduate students

* Jerome Gray, UF
* Nadege Charles, UF
* Kim Blenman, UF
* Kimberly Aiken, UF
* Elisabeth Berg, Duke University, recipient of an Arthritis Foundation Summer student fellowship
* Kareem Abdelfatah, UF, recipient of an Arthritis Foundation Summer student fellowship
* Dane Thomas, UF.
* (High-School Student)
* Kenji Kayes, UF
* Aaron Brice, UF
* Elsa Santillana, UF
* Stephanie Montenegro, UF
* Yunfai Ng, UF
* Mohamad Zadeh, UF
* Hope Summers, SF2UF
* Brian Robusto, UF University Scholar.
* Lucas James
* Nikita Kostrubsky
* Ivey Bush, SF2UF
* Claudia Zamora
* Valentina Testa
* Mohamed Elashry
* Olivia Charland

Student Science Training Program (High School Seniors)

* Shrivani Parick, (summer 2008)
* Kate Bautista (summer 2011)
* Sidney Korsunky (summer 2014)

Advisory boards

* External Advisory Board Member, Center for Childhood Obesity Prevention, Arkansas Children’s Research Institute, 2019-2024.
* UF pediatric rheumatology fellowship training program: non-clinical advisor, 2018-present.

**INVITED TALKS**

1. Arthritis Foundation, North Florida Chapter: “Genetic analysis of SLE in a mouse model”. March 29, 1997, Gainesville, Fl.
2. The Richard and Nancy Leeds Seminars in Experimental Pathology: “Functional and genetic dissection of a murine model of SLE”. October 27, 1998, Northshore University Hospital, Manhasset, NY.
3. Aventis Pharmaceuticals: “Genetics of SLE in a mouse model” Bridgewater, NJ, January 22, 2001.
4. The Lupus Genetics Conference, Oklahoma Medical Research Foundation, Oklahoma City, Ok, “Functional Differences Between the *Sle1* Loci Revealed through Their Interactions With Other SLE Susceptibility Genes”, September 9, 2001.
5. Yale Immunobiology Seminar SeriesYale University, “Functional and Genetic Analysis of the *Sle1* Locus" October 18, 2001
6. Hospital for Special Surgery, New York, NY, “Functional and Genetic Analysis of the *Sle1* Locus" October 19, 2001.

# Mouse Genetics Advanced Course, December 17-21, 2001, Pasteur Institute, Paris, France

1. Toronto Western Research Institute, Toronto, Canada “Functional analysis of the Sle1 locus and its interactions with other SLE-susceptibility loci” February 19, 2002.
2. Dartmouth University, Lebanon, NH, “Genetic analysis of lupus susceptibility and sepsis resistance in the NZM2410 mouse” May 6, 2002.
3. Molecular Biology and Immunology Interdisciplinary Graduate Program, University of Iowa, Iowa City, IO, “Genetic analysis of lupus susceptibility in a mouse model”, September 11, 2002.

# Mouse Genetics Advanced Course, December 15-19, 2002, Pasteur Institute, Paris, France

1. NIEHS workshop: Environmental factors in autoimmune disease, Durham, NC: “Congenic strains as a tool to analyze gene / environment interactions in autoimmune diseases”, Feb 4-5, 2003
2. Genetic and Translational Medicine Center, University of Alabama at Birmingham, “Genetic analysis of lupus susceptibility in a mouse model”, March 17, 2003.
3. Workshop on the Genetics and Mechanisms of Autoimmunity, “Using BCR transgenics in the NZM model” Princeton, NJ; March 21-23
4. Workshop on Collaborative Approaches to Genetics of Rheumatic Diseases, NIH/NIAMS, Bethesda, MD, June 24-25, 2003.
5. University of Virginia SCOR on SLE symposium, “Genetics of SLE in the NZM2410 model”, Charlottesville, VA, Oct. 1-2, 2004.
6. Department of Oral Biology, College of Dentistry, University of Florida, “The hunt of lupus genes”, March 14, 2005.
7. Mayo Clinic, Department of Immunology “Genetic analysis of lupus susceptibility in a mouse model”, Rochester MN, May 19, 2005.
8. Aegean Conference: Autoimmunity: Mechanisms and Novel Treatments” Santorini, Greece, September 25-30, 2005.
9. NIH-NIAMS, Autoimmunity Branch: Genetics of B cell contribution to SLE in a murine model, February 15, 2006.
10. Medical College of Georgia, Center for Biotechnology and Genomic Medicine: “Genetic analysis of lupus susceptibility in a mouse model”, Augusta, GA, March 6, 2006.
11. Jacksonville University, Science and Engineering Lecture Series: “Genetic analysis of lupus using a mouse model”, Jacksonville, Fl, March 29, 2006.
12. University of Nebraska, Department of Genetics, Cell Biology and Anatomy: “Using congenic analysis to find lupus susceptibility genes”, Omaha, NE, May 5, 2006.
13. Rigel Pharmaceutical Inc. Lupus Day 2006 “The B6.Sle1.Sle2.Sle3 triple congenic mouse as a model of lupus”, San Francisco, CA, June 1, 2006.
14. University of Alabama at Birmingham "Genetics of analysis of autoreactive B cells in a murine model of lupus", Birmingham, Al., January 9, 2007.
15. Harvard Medical School, Division of Immunology "Genetic and functional analysis of the Sle1a lupus susceptibility locus", Boston, MA, February 13, 2007.
16. Oklahoma Medical Research Foundation "Genetic determination of T cell autoreactivity in a mouse model of lupus", Oklahoma City, OK, May 31, 2007.
17. Harvard Institutes of Medicine First Lupus Symposium: "The Sle1c murine lupus susceptibility locus", Boston, MA, Sept. 7, 2007.
18. University of Florida Genetics Institute: “Genetic analysis of lupus using a mouse model”, Gainesville, Fl, Oct. 18, 2007.
19. University of Colorado Health Science Center, Division of Rheumatology, Department of Medicine and Department of Integrated Immunology: "Genetic and functional analysis of the Sle1c locus", Denver, CO, Jan. 29, 2008.
20. Thomas Jefferson University, Department of Microbiology and Immunology: "Genetic analysis of systemic lupus erythematosus in a mouse model", Philadelphia, PA, Feb. 28, 2008.
21. Temple University, Department of Microbiology and Immunology: "Genetic analysis of systemic lupus erythematosus in a mouse model", Philadelphia, PA, Feb. 29, 2008.
22. Merinoff Symposium “Systemic Lupus: Bringing Science to the Patient”: "Chasing genes involved in tolerance to nuclear antigens", Mohonk Mountain House, NY, September 24-27, 2008.
23. UTSW, Department of Immunology seminars series: “The Sle1 SLE susceptibility locus”. Dallas, TX, December 10, 2008.
24. 17th annual meeting of the Henry Kunkel Society: “Genetic determination of autoreactive T cells in a mouse model of lupus”. The Rockefeller University, New York, April 22-25, 2009
25. UAB Division of Rheumatology and Clinical Medicine: “Using a Mouse Model to Dissect Lupus Pathogenesis”, Birmingham, AL, July 15, 2009.
26. UF Department of Microbiology and Cell Science: “Genetic determination of autoreactive T cells in a mouse model of lupus”. Gainesville, FL, November 30, 2009.
27. Medical College of Georgia Department of Medicine: “Genetic of lupus: updates from the NZM2410 model”, Augusta, GA, April 19, 2010.
28. 18th annual meeting of the Henry Kunkel Society: “The cell cyclin kinase inhibitor *Cdkn2c* contributes to lupus susceptibility by regulating B and T cell homeostasis and differentiation”. The Rockefeller University, New York, NY, April 21-24, 2010.
29. Alliance for Lupus Research Meeting: “Retinoic acid regulation of T cell homeostasis in lupus”, New York, May 17, 2010.
30. Feinstein Institute’s Center for Autoimmune Diseases: “Genetic of lupus: lessons learned from the *Sle1* locus”, Manhassett, NY, May 18, 2010.
31. 9th International Congress on Systemic Lupus Erythematosus: “Genetics of lupus: what did we learned from the mouse?” Vancouver, Canada, June 24-27, 2010.
32. Gwen Knapp Center for Lupus and Immunology Research Symposium: “Mechanisms of autoreactive B cell activation in the NZM2410 model” University of Chicago, October 8-9, 2010.
33. Carter Immunology Center University of Virginia, “Genetic dissection of the NZM2410 mouse model of lupus”. September 19, 2011.
34. Department of Immunology, Lerner Research Institute, Cleveland Clinic, “Dissection of the murine *Sle1* lupus susceptibility locus”. November 16, 2011.
35. Pfizer Lupus mini-symposium, December 2, 2011, Cambridge, MA.
36. Merck Invited speaker, March 9, 2012, Cambridge, MA.
37. Nature Immunology and Hudson Alpha Immunogenomics meeting: “Lupus susceptibility genes: how to use the mouse to decipher human lupus pathogenesis” October 1-3, 2012, Huntsville, AL.
38. 2012 International Forum of Stem Cell and Regenerative Medicine and the Symposium for New Advance of Mesenchymal Stem Cell Therapy in Autoimmune Disease. “Regulation of MSC function by the lupus susceptibility gene Pbx1”. Dec 7-9, 2012 Nanjing, China
39. Department of Rheumatology, Capital Medical University. “Murine models of SLE”, Beijing, China, December 14, 2012.
40. Alliance for Lupus Research 2013 Symposium: “T cell metabolism defects in lupus” New York, NY, June 3-4, 2013.
41. UAB 2013 Spring Immunology Symposium, “T cell metabolism defects in lupus”. Birmingham, AL, June 22-23, 2013.
42. 5th International conference on B cells and autoimmunity, “Genetic and functional analysis of B cell defects in a mouse model of lupus”, Como, Italy, Aug. 19-21, 2013.
43. Distinguished Speaker for the Microbiology and Immunology Seminar Series, University of Louisville, “Genetic analysis of lupus susceptibility: Tracking down a gene that regulates T cell autoreactivity”, Louisville, KY, September 19, 2013.
44. University of Florida Center for Inflammation & Mucosal Immunology Symposium, “CD4+ T Cell Metabolism in SLE”, Gainesville, FL, October 19, 2013.
45. Department of Medicine Division of Rheumatology, Northwestern University, Grand Round lecture ““Genetic analysis of lupus susceptibility: Tracking down a gene that regulates T cell autoreactivity”, Chicago, IL, January 16, 2014.
46. The Jackson Laboratory “Metabolic inhibitors as a treatment for lupus in the B6.Sle1.Sle2.Sle3 mouse model”, Bar Harbor, ME, January 20, 2014.
47. Pennsylvania State University College of Medicine, Dept. of Microbiology and Immunology seminar series. “Genetic determination of autoreactive CD4 T cells in lupus”. Hershey, PA, February 27, 2014.
48. UF-HHMI Science for Life seminar: “Pathogenesis of Systemic Lupus Erythematosus” April 10, 2014.
49. UF MD-PhD Training Program / Monthly Educational Dinner “Genetics of Systemic Lupus Erythematosus”. April 16, 2014.
50. Feinstein Institute for Medical Research. “Genetics of B1a cell expansion in the NZM2410 mouse model of lupus erythematosus”. May 7, 2014
51. Alliance for Lupus Research 2014 Symposium: “T cell metabolism defects as target in lupus” New York, NY, May 8-9, 2014.
52. Merinoff World Congress 2014: B-1 Cell Development and Function. “Genetics of B1a cell expansion in the NZM2410 mouse model of lupus erythematosus”. Tarrytown, NY, **June 16-19th, 2014.**
53. **Biogen: “**The B6.NZM2410.Sle1.Sle2.Sle3 mouse model of SLE”. Boston, Ma, January 20, 2015.
54. UF Department of Medicine Division of Rheumatology Ground Rounds: “Normalization of CD4+ T Cell Metabolism Reverses Lupus”, March 13, 2015.
55. Lupus Foundation of Florida: Living Well with Lupus workshop: “Immune metabolism and lupus”. Gainesville, Fl, March 21, 2015.
56. 3rd Metabolism Mini Symposium: “Immune metabolism and lupus”.Vesalius Research Center, VIB KU Leuven, Belgium, May 7, 2015.
57. Immunopharmacology – Vaccipharmacia 2015: “Immune metabolism and lupus”. Varadero Beach, Cuba, June 14-19, 2015.
58. Forum for Discovery 15th Annual Scientific conference: “CD4 T cell metabolism in SLE: Characterization and target identification”, New York, NY, October 19-20, 2015.
59. UF Department of Medicine Division of Endocrinology Ground Rounds” Metformin as a regulator of immune cell metabolism”, November 4, 2015.
60. American College of Rheumatology annual meeting: “Therapeutic targeting of CD4+ T Cell Metabolism in Murine Models of Lupus”, San Francisco, CA, November 8, 2015.
61. Keystone Symposium: Immunometabolism in Immune Function and Inflammatory Disease: Targeting CD4+ T cell metabolism in lupus, Feb, 21-25, 2016.
62. Seminars in Oral Biology, UF College of Dentistry: Roads less traveled to understand lupus: immunometabolism, microbiome and mesenchymal stem cells, April 18, 2016.
63. ADA 76th meeting, Immune Cell Metabolic Demand Symposium. “T cell metabolism in autoimmunity**”** New Orleans, June 7, 2016.
64. CIMI minisymposium: “Gut dysbiosis in lupus”. Gainesville, FL, June 28, 2016.
65. Department of Microbiology and Immunology, University of Miami School of Medicine: “Immunometabolism defects in systemic lupus erythematosus: mechanisms and therapeutic opportunities” Miami, Fl, July 19, 2016.
66. The Jackson Laboratory “Immunometabolism defects in systemic lupus erythematosus: mechanisms and therapeutic opportunities”, Bar Harbor, ME, August 4, 2016.
67. 6th International Conference on B Cells and Autoimmunity. "B cells induce inflammatory T cell differentiation in a mouse model of lupus". Sun Moon Lake, Taiwan, August 16-18, 2016.
68. American Autoimmune Related Disease Association Symposium Novel Cellular Pathways in Autoimmunity: “Spontaneous Follicular T Helper Cells in Lupus-Prone Mice Have Unique Metabolic Requirements”. Washington, D.C., September 24, 2016.
69. Lupus 2016. Glucose Oxidation in Lupus T Cells. Armok, NY, September 29-October 1, 2016
70. Lupus 2016. “Spontaneous Follicular T Helper Cells in Lupus-Prone Mice Have Unique Metabolic Requirements”. Armok, NY, September 29-October 1, 2016
71. Department of Immunology, University of Toronto. “Immunometabolism defects in systemic lupus erythematosus: mechanisms and therapeutic opportunities”. Toronto, CN October 7, 2016.
72. ACR Basic Research Conference: “T cell metabolism in SLE”. Washington, DC, November 12, 2016.
73. CIMI 4th Annual Research Retreat: “Microbial dysbiosis drives systemic autoimmunity in a mouse model of lupus”. Gainesville, FL, November 18, 2016.
74. Lupus Research at UF. SF2UF bridge program, Santa Fe College, January 31, 2017.
75. “Environmental exposures and the development of systemic lupus erythematosus: review of epidemiological studies and evidence from mouse models”. Center for Environmental and Human Toxicology, University of Florida, February 28, 2017.
76. “Immunometabolism defects in systemic lupus erythematosus: mechanisms and therapeutic opportunities”. Connective Tissue Disease workshop, Shanghai JiaoTong University School of Medicine, Shanghai, 200001, China, March 25, 2017.
77. “Immunometabolism defects in systemic lupus erythematosus: mechanisms and therapeutic opportunities”. Lupus 2017, Melbourne, Australia, March 26-29, 2017.
78. Unique requirement of high levels of glucose metabolism by autoreactive follicular helper T cells**.** Keystone Symposium: Integrating Metabolism and Immunity, Dublin, Ireland. May 29-June 2, 2017.
79. Metabolic regulation in T cells in lupus. FASEB Autoimmunity conference, Saxton River, Vt, July 10-14, 2017.
80. “Translational research in lupus”. 1st Florida Translational Cell Biology Symposium*,* Gainesville, Fl, September 22, 2017.
81. *“*Metformin treatment in lupus: evidence from mouse models and patient T cells”. Metformin: translating Biology into the Clinic, The Banbury Center at CSH, NY, September 24-27, 2017.
82. “The roads less traveled to understand lupus: Metabolism, microbiome and mesenchymal stem cells”. Feinstein Institute, Manhasset, NY, September 27, 2017.
83. **“**Immunometabolism defects in SLE: mechanisms and therapeutic opportunities**”,** Jansen, Torrey Pines, CA, Nov. 9, 2017.
84. “Metabolic checkpoints in lupus”. Advances in Autoimmunity, Third Annual Colton Center Symposium, NYU, Dec. 4, 2017.
85. ImmunoTex Summit: Metabolism of lupus CD4 T cells, San Diego, CA, Jan 30, 2018.
86. European Lupus Meeting, “Immunometabolism in systemic lupus erythematosus”. Dusseldof, Germany, March 21-24, 2018.
87. “Immunometabolism defects in SLE: mechanisms and therapeutic opportunities” Division of Pulmonary Medicine, University of Florida, April 4, 2018.
88. Immunometabolism defects in SLE: Mechanisms and therapeutic opportunities. Department of Microbiology and Immunology, Vanderbilt University, May 15, 2018.
89. “A year in review of translational research in lupus”. Lupus 21st Century, Armonk, NY, September 14, 2018.
90. “A year in review of translational research in lupus”. UF Division of Rheumatology Gran Rounds, Gainesville, Fl, September 28, 2018.
91. “Metabolic checkpoints in lupus”. Janssen Immunometabolism Scientific Advisory Board, London, UK, October 14, 2018.
92. “Metabolic determinants of lupus pathogenesis”, Department of Immunology,UTSW, Dallas, Tx, October 15, 2018
93. “Metabolic regulation of T cell function in lupus” 2018 Autumn Immunology Conference: Chicago, IL, Nov. 16-19, 2018.
94. “Metabolic regulation of T cell function in lupus” Lupus Discovery 2018: New York, NY, December 2018
95. “Deciphering cellular metabolism to understand the mechanisms of immune activation and to discover therapeutic targets”. Agilent Cell Analysis User Group Meeting. Moffitt Cancer Center, Tampa. Fl, Feb 27, 2019.
96. “Metabolic regulation of autoimmunity in lupus”. AAI 2019 Major symposium: Regulating Immune cell Metabolism to Regulate Immune Responses, San Diego, CA, May 13, 2019.
97. “Gut dysbiosis, tryptophan metabolism and systemic lupus erythematosus”. UF CMII Minisymposium, Gainesville, Fl, May 21, 2019.
98. “Gut dysbiosis and systemic lupus erythematosus”. USF-UF joint Microbiome workshop, Tampa, Fl, May 28, 2019
99. “Tryptophan metabolism, microbiome and lupus”. Lankenau Institute for Medical Research, Wynnewood, PA, June 6, 2019
100. “Metabolic checkpoints in systemic lupus erythematosus. Immunometabolism”. Fundamentals to Prospective New Therapies ABCAM conference. Boston, MA, June 25-26, 2019.
101. “Immunometabolism defects in SLE: mechanisms and therapeutic opportunities”.Shanghai Puji CTD Workshop 2019, Shanghai, PRC, August 24-25, 2019.
102. “Enhanced resistance to viral infection as a trade of for autoimmunity”, University of Central Florida, September 20, 2019.
103. “Regulation of lupus pathogenesis but the gut microbiome”, University of Western Michigan School of medicine, October 1, 2019.
104. “Metabolic checkpoints in systemic lupus erythematosus. Immunometabolism”. [Immunometabolism 2019](https://urldefense.proofpoint.com/v2/url?u=https-3A__nyas.us13.list-2Dmanage.com_track_click-3Fu-3Dcce5d9495ba8e5717fdab6ede-26id-3Dd631baa448-26e-3D65d1802c42&d=DwMFaQ&c=sJ6xIWYx-zLMB3EPkvcnVg&r=kDNjmxykhBz_bZ-z5o85nA&m=SJ7rR359jfZwXOEj8n3ZJfXarXwz8uMwXIRItcC30T8&s=oMrhqZ-H49Omg6bqjKm7aMdHnomnPXGajvbMEUBUFwg&e=), New York Academy of Science, October 22, 2019.
105. “Immunometabolism and Autoimmune Disease. Immunometabolism”. American College of Rheumatology Annual conference, Atlanta, GA, Nov. 12, 2019.
106. “Immune metabolism regulation of lupus”. Oklahoma Research Foundation, December 5, 2019.
107. **“**An Overview of Autoimmune Diseases**”** Oak Hammock Learning in Retirement (ILR) Science Program, the Oak Hammock at the University of Florida, Jan. 6, 20020.

**EDITORIAL BOARDS OF SCIENTIFIC JOURNALS**

|  |  |  |
| --- | --- | --- |
| * Autoimmunity, Editorial Board Member, 2005 - 2008. | |  |
| * BMC Immunology, Associate Editor, 2008 - 2010 |  |  |
| * BMC Immunology, Editorial Board Member, 2004 - 2013. | |  |
| * BMC Immunology, Immunogenetics Section Editor 2010 - 2013 | |  |
| * Clinical and Translational Sciences Editorial Board Member, 2007 - . | | |
| * Frontiers in Biosciences, Managing Editor, 2006. | |  |
| * Immunology and Cell Biology, Editorial Board Member, 2007 - 2012. | | |
| * Journal of Immunology, Associate Editor 2009 - 2013. | |  |
| * Laboratory Investigation, Associate Editor, 2003 – 2008. | |  |
| * Laboratory Investigation, Editorial Board Member, 2008 - .2012 * Frontiers in B cell biology: Review Editorial Board Member, 2010 – 2018. * Arthritis & Rheumatism: Advisory Editor, December 2012- * Journal of Immunology, Section Editor 2013-2016 * Genes and Immunity, editorial Board Member 2013-2017 * Arthritis Research and Therapy, Associate Editor of the Immunology and Pathology Section, 2015 -17 * Frontiers in Immunology: Associate Editor of the Editorial Frontiers Autoimmune and Autoinflammatory Disorders, 2017- * Immunometabolism: 2019-2022. | |  |

**AD HOC PEER-REVIEWS FOR SCIENTIFIC JOURNALS**

|  |
| --- |
| * AJP- Heart and Circulatory Physiology |
| * Annals of the Rheumatic Diseases * Arthritis and Rheumatism |
| * Arthritis Research and Therapy |
| * Autoimmunity |
| * Blood |
| * BMC Immunology |
| * BMC Medical Genetics * BMC Medicine |
| * British Journal of Dermatology * Cell Metabolism * Cell Transplantation * Cellular Immunology * Clinical and Developmental Immunology |
| * Clinical and Experimental Immunology |
| * Clinical Experimental Rheumatology * Clinical Immunology * Current Aging Science |
| * Current Molecular Medicine |
| * Diabetes |
| * European Journal of Immunology |
| * Frontiers in Immunology * Future Rheumatology |
| * Genes and Immunity |
| * Genomics * Immunity, Inflammation, and Disease |
| * ImmunoHorizons * Immunology |
| * Immunotherapy |
| * International Journal of Rheumatic Diseases * Journal of Autoimmunity |
| * Journal of Clinical Immunology * Journal of Clinical Investigation |
| * Journal of Immunology * Journal of Leukocyte Biology |
| * Journal of Molecular Medicine |
| * Journal of the American Society of Nephrology |
| * Laboratory Investigation * Lupus |
| * Mammalian Genome |
| * Molecular Basis of Disease * Molecular Psychiatry * Molecular Therapy |
| * Nature * Nature Communications |
| * Nature Genetics |
| * Nature Reviews Rheumatology * Nature Scientific Reports |
| * Plos Genetics * Plos One * Proceedings of the National Academy of Sciences * Science Immunology * Science Reports * Science Signaling * Science Translational Medicine * Trends in Molecular Medicine |

National / International meeting session Chair:

* Chair of the “Immunopathogenesis of Systemic Lupus” Block Symposium at the AAI annual meeting - EB’98.
* Chair of the “Genetics of autoimmunity” Block Symposium at the AAI annual meeting, Denver, Co, May 8, 2003.
* Meeting Co-Organizer: 9th International Workshop on Autoantibodies and Autoimmunity, Gainesville, FL, Sept. 29- Oct. 2, 2005.
* Chair of the concurrent session: Epigenetics and Lupus. 9th International Congress on Systemic Lupus Erythematosus. Vancouver, Canada, June 25, 2010
* Chair of the plenary session: SLE: of mice and women. 9th International Congress on Systemic Lupus Erythematosus. Vancouver, Canada, June 27, 2010.
* Chair of the “Genetics of autoimmune diseases” block-symposium, AAI meeting, Boston, MA, May 7, 2012.
* Co-chair for the Systemic Lupus Erythematosus - Animal Models abstract selection, ACR meeting, San Diego CA, October 25-30, 2013.
* Chair of the “T cell in autoimmunity II” block-symposium, AAI meeting, Pittsburg, PA, May 6, 2014.
* Co-chair for the Systemic Lupus Erythematosus - Animal Models abstract selection, ACR meeting, San Francisco CA, November 14-17, 2015.
* Keystone Symposium: Immunometabolism in Immune Function and Inflammatory, workshop co-Chair, Banff, AB, Canada, Feb, 21-25, 2016.
* Chair of Basic Autoimmunity, AAI meeting, Seattle, WA, May13-17, 2016.
* Co-organizer of the ACR Basic Research Conference “Cellular metabolism and stress response in immune-mediated inflammatory disease”. ACR 2016, Washington, D.C., Nov 11-12, 2016.
* Chair of Basic Autoimmunity, Block Symposium Triggers and Tolerance in Autoimmunity, AAI 2017, Washington, D.C.
* Co-chair for the B cell abstract selection, ACR 2017 meeting
* Co-chair Lupus 2017, Melbourne, Australia, March 26-29, 2017
* Co-chair Keystone Symposium: Integrating Metabolism and Immunity, Dublin, Ireland. May 29-June 2, 2017.
* Co-chair FASEB Autoimmunity conference, Saxton River, Vt, July 10-14, 2017.
* Co-chair Treatment Strategies in Systemic Autoimmunity AAI meeting, May 6, 2018, Austin TX.
* Co-chair Regulation of T – B interaction: Workshop. Lupus 21st Century, Armonk, NY, September 14, 2018.
* Co-Chair: AAI 2019 Major symposium: Regulating Immune cell Metabolism to Regulate Immune Responses, San Diego, CA, May 13, 2019.
* Chair: ACR 2019: Animal Models of lupus, Atlanta, GA, Nov. 10, 2019.

Requested evaluation for promotion and tenure at:

* Imperial College, London UK
* University of North Carolina, Department of Immunology and Microbiology
* University of Nebraska, Department of Genetics, Cell Biology and Anatomy, (2 reviews)
* Oklahoma Medical Research Foundation
* Tel Aviv University, Department of Clinical Microbiology and Immunology
* Temple University, Department of Medicine, Division of Rheumatology.
* Cleveland Clinic Learner Center
* University of Virginia, Department of Microbiology and Immunology
* Georgia Regents University Cancer Center
* Penn State Hershey College of Medicine
* University of Houston
* University of Toronto